Vorinostat (SAHA)

Name: Vorinostat (SAHA)
Brand: Selleck Chemicals
SKU: S1047
Rating: 5 (305 reviews)

For research use only.

Catalog No.S1047 Synonyms: MK0683

305 publications

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Selleck's Vorinostat (SAHA) has been cited by 305 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )

Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )

J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )
ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )
Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )
Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )
J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )
Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )
Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )
PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )
Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )
Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )
Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )
Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )
Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	M{j0XmtqdmG\|ZTDBd5NigQ>?		M1rVXFEhcA>?	MVjEUXNQ	NUXT[lFO[W62aT3ISGFEOSCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yOTJizszN	MmrCNVE6PjB2OEm=
Friend leukemic cell	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XWd\|UxKM7:TR?=	NGq4cJI4OiCq	NXHm[mlSTE2VTx?=	MUfJR\|UxRTBwOUmg{txO	NWfLPGJwOTJzMEm5NVM>
K562	MWfLbY5ie2ViQYPzZZk>		M4TDdlYhcA>?	Mkm2SG1UVw>?	NHjCdGVKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViKH3pfJR2emVib3[gTGRCSzFiYX7kJGhFSUN{KTD3bZRpKEmFNUCgc4YhOC5yMTFOwG0>	MWWxNlQyQTN6MB?=
HT1080	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnL3O\|IhcA>?	NGfoUo5FVVOR	NUPXXYF6UUN3ME2yMlQh\|ryP	NHHo[JgyOjJ5MEG3OS=>
H1299	M2K5dWtqdmG\|ZTDBd5NigQ>?		MVGyNEBucW5?	Mn\vSG1UVw>?	MoLyTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	MW[xOFUzOTR{Mh?=
H1299	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2fySVczKGh?	M2DGWmROW09?	MYDJR\|UxRTdwMkSg{txO	NVT6SXBuOTR3MkG0NlI>
HeLa	NE[wfZBMcW6jc3WgRZN{[Xl?		MWizNEBucW5?		NFHFb3hKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDobZN1d26nIHTlZYNmfHmuYYPlJJdqfGhiSVO1NEBw\iByLkK4JO69VQ>?	NUnMR412OTV4MEO5OFk>
LOX-IMVI	NGDwbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWG0PEBp		NF7NXJhKSzVyPUGuN{DPxE1?	Ml;mNVU4OTV2N{C=
NCI-H226	NUHaelVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUG0PEBp		NUjwPFNnUUN3ME2yMlYh\|ryP	NVHTcoZ7OTV5MUW0O\|A>
RXF-631L	NXe5dnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUe0PEBp		NXr2OG1nUUN3ME2yJO69VQ>?	NGPlT24yPTdzNUS3NC=>
SNB-78	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlrJOFghcA>?		MYnJR\|UxRTF4IN88US=>	MY[xOVcyPTR5MB?=
St-4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIrkXVQ1QCCq		MnzFTWM2OD13LkKg{txO	NGPv[mYyPTdzNUS3NC=>
ARP1	M4PIXmZ2dmO2aX;uJGF{e2G7	NF\WVGQzKM7:TR?=	MUC2JIg>		M1Tuemlv\HWldHnvckBw\iCSMkHXRWYyKGenbnWg[ZhxemW\|c3nvci=>	MmLHNVQ4OzR6ME[=
CEM	M{HIUGtqdmG\|ZTDBd5NigQ>?		MnL4NUBp	M3rv[2ROW09?	Mn:yTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>?	MnfhNVY1OjByNkS=
HCT15	NXi5eWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3PQW\|Q5KGh?		NXzKVnFET0l3ME2wMlgzKM7:TR?=	NEHINVAyPjd{M{KyOy=>
NCI-H23	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoS2OFghcA>?		MUnHTVUxRTBwOUKg{txO	M4nkN\|E3PzJ\|MkK3
GM15850	MlLUT4lv[XOnIFHzd4F6	NWfCSXhXOi53IN88US=>	NUXnbZkxQTZiaB?=	MkfnSG1UVw>?	MWfJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViMUSgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	MmGzNVY6OjF\|Nke=
GM15850	MVrLbY5ie2ViQYPzZZk>	NYDJ[GJpOi53IN88US=>	MnHaPVYhcA>?	NXrYS244TE2VTx?=	NFLqXW5KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	MmXxNVY6OjF\|Nke=
GM15850	M2rlO2tqdmG\|ZTDBd5NigQ>?	MnP6Nk42KM7:TR?=	NXXscoFIQTZiaB?=	M{[yZWROW09?	MXnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMUKgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	Mlm3NVY6OjF\|Nke=
GM15850	MUXLbY5ie2ViQYPzZZk>	NWf5WlJtOi53IN88US=>	NUDsU5Q5QTZiaB?=	NESwNVlFVVOR	MlywTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEmgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	M3zqWVE3QTJzM{[3
GM15850	NVXVUGZQU2mwYYPlJGF{e2G7	M{XTUVIvPSEQvF2=	NV7rbGhkQTZiaB?=	M17IO2ROW09?	Mn\kTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEigZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	M3vqXlE3QTJzM{[3
GM15850	NF\pVGhMcW6jc3WgRZN{[Xl?	MkGyNk42KM7:TR?=	MYC5OkBp	M4rn[WROW09?	NHjwdnFKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MkXlNVY6OjF\|Nke=
U937	MX3GeY5kfGmxbjDBd5NigQ>?	NUTYSnZIPSEQvF2=	NVjRbmQyOjRiaB?=	MUDEUXNQ	NIe4cZVE\WyuIHP5Z4xmKGG{cnXzeEBjgSCjY3P1cZVt[XSrb36gZZQhWy:JMj;NJJBp[XOn	NF\NdGcyPzByNEexPC=>
H661	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXHPN2pGPDhiaB?=		MnraTWM2OD1zIN88US=>	NFHub\|YyPzF3N{CwPS=>
U937	MXHGeY5kfGmxbjDBd5NigQ>?	MUS1JO69VQ>?	NH;yVXEzPCCq	MXjEUXNQ	MlnOTY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	NVXKUXJzOTd2NEe3OVA>
U937	NYHB[po{TnWwY4Tpc44hSXO\|YYm=	Ml7XNUDPxE1?	MX2yOEBp	MX;EUXNQ	NWPiUJRRTW[oZXP0JI9vKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44>	NF3JXXEyPzR2N{e1NC=>
RAW264.7	M3nMNWZ2dmO2aX;uJGF{e2G7	NEHsXlcyOCEQvF2=	NXfYXGxvOjSq	NILxdHh4[XSnch?=	M3rTdWlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhXE6IYXzwbIEheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE44PiEQvF2=	MVKxO\|Q4PzVzOB?=
RAW264.7	MUjGeY5kfGmxbjDBd5NigQ>?	MXWxNEDPxE1?	NGjZWIEzPGh?	M1XCOpdifGW{	MYDJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJG5QKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFEvQDhizszN	MlH1NVc1Pzd3MUi=
SC9	M2W3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mm\KOFghcA>?		M2fnN2lEPTB;MD62NFYh\|ryP	MVGxO\|UxPzJzOR?=
ST14A	MU\GeY5kfGmxbjDBd5NigQ>?	NWTGTZUzPSCwTR?=	MnLFO\|IhcA>?		NV;keXdxUW6lcnXhd4UhcW5iUlXTWE9PWlOIIH3SUmEh\XiycnXzd4lwdg>?	MlfoNVc2PjV7OUO=
ST14A	MlWySpVv[3Srb36gRZN{[Xl?	MmjSOUBvVQ>?	M{foPFczKGh?		NEfLWGtKdmO{ZXHz[UBqdiCHMl[xJI1TVkFiZYjwdoV{e2mxbh?=	MlvWNVc2PjV7OUO=
PANC1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf6SIYyKM7:TR?=			NEPXdWtKSzVyPUCuOFUh\|ryP	NUjrVZJiOTd3OEi3OFQ>
PANC1	MkHBSpVv[3Srb36gRZN{[Xl?	M4jv[\|Eh\|ryP	NE\LV2EzPCCq		MojnTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	NYrtZpFmOTd3OEi3OFQ>
PANC1	NITGWppHfW6ldHnvckBCe3OjeR?=	MlLINUDPxE1?	MU[yOEBp		M3f3Tmlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	MnfNNVc2QDh5NES=
PT45	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDP[JhKSzVyPUSg{txO	NEjCRYoyPzV6OEe0OC=>
ACHN	NFTjVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmjxNlEhcA>?		MVXHTVUxRTBwNkWg{txO	NX[4NlJPOTd4NkK2NFY>
PC3	NVHFfItQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEjTeowzOSCq		MnX3S2k2OD1yLkexJO69VQ>?	NFGzcGcyPzZ4Mk[wOi=>
A431	M3jIXWN6fG:2b4jpZ{BCe3OjeR?=		Mk\IO\|IhcA>?		M2jMR2lEPTB;ND6yJO69VQ>?	MXGxO\|Y6OTd4Mx?=
Cal27	MXfDfZRwfG:6aXOgRZN{[Xl?		NGDOSoc4OiCq		NELDXmZKSzVyPUOuNkDPxE1?	M{nZcFE4PjlzN{[z
CCRF-CEM	M2f5ZmN6fG:2b4jpZ{BCe3OjeR?=		NEjXcnc4OiCq		NED5WmNKSzVyPUCuPEDPxE1?	NFjWTXMyPzZ7MUe2Ny=>
EOL1	M3zVZmN6fG:2b4jpZ{BCe3OjeR?=		NYXXfHFIPzJiaB?=		M3PvWmlEPTB;MTFOwG0>	MWqxO\|Y6OTd4Mx?=
Hec-1-A	M{C5SGN6fG:2b4jpZ{BCe3OjeR?=		NHrKc5U4OiCq		MX7JR\|UxRTFizszN	M2rtOVE4PjlzN{[z
HeLa	NHrvWpRMcW6jc3WgRZN{[Xl?	NYfDdVd6OTBizszN	M4DSRlMxKG2rbh?=	NUfSd4lXTE2VTx?=	NIHBfI9KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	MnzJNVc3QTF5NkO=
RKOp21	NW\CcFVRS3m2b4TvfIlkKEG\|c3H5		NXfRXG02PzJiaB?=		MXTJR\|UxRTFwN{[g{txO	MnTtNVc3QTF5NkO=
Saos2	NELhemVEgXSxdH;4bYMhSXO\|YYm=		M3\wVFczKGh?		NGPkVWdKSzVyPUKuN{DPxE1?	NWTXb5pUOTd4OUG3OlM>
SK-OV-3	MWDDfZRwfG:6aXOgRZN{[Xl?		MoS2O\|IhcA>?		Mn;iTWM2OD1{LkKg{txO	M4XMTlE4PjlzN{[z
U87MG	MVLDfZRwfG:6aXOgRZN{[Xl?		MmrBO\|IhcA>?		M4P2XWlEPTB;MUGg{txO	M1vYdVE4PjlzN{[z
NUGC3	NUn3bIlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1niU\|Uh\|ryP	M4W2[FI1KGh?		MnTRS2k2OD1{Lke5JO69VQ>?	M{TwbFE4QTB2OESz
CCD1059SK	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\5TWM2OD12Mz61JO69VQ>?	M3zDOVE5OjR5NUW0
HepG2	M3rPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTBwMECwOkDPxE1?	MlPnNVgzPDd3NUS=
HT1080	M{XGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTqfYRVUUN3ME2wMlAxOjRizszN	NVSzXZVXOTh{NEe1OVQ>
SKBR3	M2fJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHEfIlKSzVyPUCuPEDPxE1?	MlrxNVgzPDd3NUS=
SNB78	NF61bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnSV3Z1TUN3ME2xOkDPxE1?	NFTHOVgyQDJ2N{W1OC=>
SQ20B	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUGx[W0zUUN3ME2zJO69VQ>?	NXLIb3BzOTh{NEe1OVQ>
St4	NYD4dotET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jUfWVEPTB;NT6yJO69VQ>?	MkXqNVgzPDd3NUS=
MCF7	NVvJT2cxTnWwY4Tpc44hSXO\|YYm=	MWSxNEDPxE1?	NYe2SYFHQCCq	NIDhcZpFVVOR	NGTLNVhKdmS3Y4Tpc44hd2ZidIXieYxqdiCqeYDldoFk\XS7bHH0bY9v	NXH6fZdQOTh{NkmyNlY>
HEK293	NUTFclRGU2mwYYPlJGF{e2G7		NGHYeIMyKGh?	MoLnSG1UVw>?	MmLkTY5pcWKrdHnvckBw\iCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6wN{DPxE1?	M1z2NFE5OzB6NU[z
HEK293	MXrLbY5ie2ViQYPzZZk>		NIjOUGgyKGh?	NFvLTZZFVVOR	MVjJcohq[mm2aX;uJI9nKEiGQVOzJJdqfGhiSVO1NEBw\iByLkC1O{DPxE1?	MX2xPFMxQDV4Mx?=
G401	MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4\xbFczKGh?	MoT0SG1UVw>?	MWTJR\|UxRTFizszN	NFXyWosyQDN5MEO3Ny=>
HeLa	NEXlTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPBOoU4OiCq	NF2zZlZFVVOR	NXn0PGVkUUN3ME2wMlQ3KM7:TR?=	MmXENVg{PzB\|N{O=
Human renal epithelial cell	M3fmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWrYSFBwPzJiaB?=	MV7EUXNQ	M{LXOWlEPTB;MUSg{txO	NHXTbI0yQDN5MEO3Ny=>
U937	NHPIbItHfW6ldHnvckBCe3OjeR?=	NFm1U4o2KM7:TR?=	M3XiS\|I1KGh?		MnXpTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>?	NEHwZVMyQDN6MUKzPC=>
U937	NHTVUnVHfW6ldHnvckBCe3OjeR?=	NXjQXI5vPSEQvF2=	NXK5SFBEOjRiaB?=		NGL2ZYhKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	NX6xWVh[OTh\|OEGyN\|g>
U937	NGPyUFZHfW6ldHnvckBCe3OjeR?=	M3fZNlUh\|ryP	M{L0dFI1KGh?		NWnXbIN5UW6mdXP0bY9vKG:oIICyNUBmgHC{ZYPzbY9v	NYq1RpZTOTh\|OEGyN\|g>
U937	MWLGeY5kfGmxbjDBd5NigQ>?	MmLSOUDPxE1?	Ml7SNlQhcA>?		NIrBcnNKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	M3HxZlE5OzhzMkO4
U937	Mlf4SpVv[3Srb36gRZN{[Xl?	NHniWlU2KM7:TR?=	MWKyOEBp		NWHUUJVqUW6mdXP0bY9vKG:oIHfyZY52dG:leYTpZ{BlcW[oZYLlcpRq[XSrb36=	M4\Xd\|E5OzhzMkO4
U937	Mn3YT4lv[XOnIFHzd4F6	NVjyVWNOPSEQvF2=	NYjt[5Z5OjRiaB?=		NGr6TmZKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx	M13CN\|E5OzhzMkO4
U937	MYLLbY5ie2ViQYPzZZk>	M2fpfVUh\|ryP	NHr1WXgzPCCq		NHTTSoxKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO0	M{HTb\|E5OzhzMkO4
HEK-TE	NVfvenFzTnWwY4Tpc44hSXO\|YYm=	MV21JO69VQ>?	M3n1[VZp	MVfEUXNQ	M1jVVmlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	Mn7nNVg1OzRzNES=
HPDE6c7	NWe0N2RvS3m2b4TvfIlkKEG\|c3H5	MU[1NEDPxE1?	MUO3NkBp	MoLTSG1UVw>?	MYXJR\|UxRTFwMzFOwG0>	MUmxPFQ6PDR4Mx?=
Human microvascular epithelial cell	M{\QfmN6fG:2b4jpZ{BCe3OjeR?=	MUC1NEDPxE1?	MXy3NkBp	NITEXXBFVVOR	M1H5U2lEPTB;MT6zJO69VQ>?	MWixPFQ6PDR4Mx?=
Hup T3	MXLDfZRwfG:6aXOgRZN{[Xl?	MVi1NEDPxE1?	NHfZfFc4Omh?	M1nV[2ROW09?	Ml3WTWM2OD1yLkig{txO	MXOxPFQ6PDR4Mx?=
Mia Paca2	M13oUGN6fG:2b4jpZ{BCe3OjeR?=	MUO1NEDPxE1?	MXu3Nog>	M4TPfWROW09?	MmPPTWM2OD1zLkGg{txO	NET4RosyQDR7NES2Ny=>
Panc 04.03	NV3ITZVjS3m2b4TvfIlkKEG\|c3H5	MnLGOVAh\|ryP	M4P2TlczcA>?	MWPEUXNQ	M1PscWlEPTB;MT6yJO69VQ>?	M4DlPFE5PDl2NE[z
SU 86.86	MX\DfZRwfG:6aXOgRZN{[Xl?	MknpOVAh\|ryP	MWm3Nog>	MnfvSG1UVw>?	M4HuUmlEPTB;MT6zJO69VQ>?	Mk\ENVg1QTR2NkO=
HEK293	MXTLbY5ie2ViQYPzZZk>		NYi1b2tKOyCq		NGjoUllKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUN4IHX4dJJme3Orb36ge4l1cCCLQ{WwJI9nKDBwMEG5JO69VQ>?	NXrkeXdEOTh3NUi2Olk>
HeLa	NHnpNoxMcW6jc3WgRZN{[Xl?		NE\RXnQzKGh?		MmXpTY5pcWKrdHnvckBw\iCwdXPs[YFzKEiGQVOge4l1cCCLQ{WwJI9nKDBwMEizJO69VQ>?	M4f6OlE5PTV6Nk[5
RAW264.7	MXrGeY5kfGmxbjDBd5NigQ>?	MlOwNkDPxE1?	MWmzMlUhcA>?	MUHEUXNQ	NUfUO45WSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJIlv\mWldHXkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?	Mo\KNVg3PDR7Nkm=
NB4			MX:0PIg>	NVK2O4l[TE2VTx?=	MU\JR\|UxRTBwNjFOwG0>	NUDQXpBHOTh5MkOzOFk>
HEK293	M2n6W2Z2dmO2aX;uJGF{e2G7	NW\0dpJpOTBizszN	NIXPR2czPCCq	M3LMc2ROW09?	MlzuRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3Xk	M{e4TlE6ODJ{Nke1
HCT116	NWW2cZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUi3Nog>	MUXEUXNQ	NGTMcIRKSzVyPUCuN\|Eh\|ryP	NUfEbVhrOTlyOESyPVQ>
HeLa	NX[4[lJXU2mwYYPlJGF{e2G7	MnvJNkDPxE1?	NFPuSmo{OCCvaX6=	NWnqbpBmTE2VTx?=	MYrJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	NV;yR\|lmOTlyOESyPVQ>
IGROV1	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NE[2R5Q4OiCq	NYi0NFkyTE2VTx?=	MorsTWM2OD1{LkKg{txO	NGHIWJQyQTB6NEK5OC=>
IGROV1	NEmwSGpMcW6jc3WgRZN{[Xl?	MoPaOUDPxE1?	MYeyOEBp	MXvEUXNQ	MYLJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMheDV\|IHHj[ZR6dGG2aX;u	M{DFflE6ODh2Mkm0
IGROV1	MlXiT4lv[XOnIFHzd4F6	NYn4dXIzOTBizszN	MYC0JIg>	M1q4[2ROW09?	MUnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[U1JPCCjY3X0fYxifGmxbh?=	NGLiW3kyQTB6NEK5OC=>
IGROV1	M2jHeWtqdmG\|ZTDBd5NigQ>?	NHXMN3UyOCEQvF2=	M1LXXlQhcA>?	MlO0SG1UVw>?	NG[1VplKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHsdIhiNXS3YoXsbY4h[WOndInsZZRqd25?	MUCxPVA5PDJ7NB?=
T24	MmfVT4lv[XOnIFHzd4F6		NV7oOoNvOyCq		NULOSVZoUW6mdXP0bY9vKG:oIHjpd5RwdmViSEOgZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNVIh\|ryP	NWjkR4dsOTlyOESzPVU>
T24	M1TzSWtqdmG\|ZTDBd5NigQ>?		NH\FTpQ{KGh?		MoK5TY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNlUh\|ryP	M3SwU\|E6ODh2M{m1
HeLa	MXzLbY5ie2ViQYPzZZk>		MnTqNVUhdWmw	NF7vVXNFVVOR	NH\uRmxKdmirYnn0bY9vKG:oIFjERWM3KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAxNjB6NUWg{txO	M3vXOVE6ODl\|OEi0
HeLa	NH[3ZZBMcW6jc3WgRZN{[Xl?		NXTQXZFwOTVibXnu	NV3aNYhmTE2VTx?=	NWTERZNkUW6qaXLpeIlwdiCxZjDISGFEQCCocn;tJI52[2ynYYKg[Zh1emGldDD3bZRpKEmFNUCgc4YhOS56NjFOwG0>	M3\CXVE6ODl\|OEi0
NCI-H69	MnjER5l1d3SxeHnjJGF{e2G7		M4TONVczKGh?	NYXUU5hRTE2VTx?=	MkfTTWM2OD1{LkC2JO69VQ>?	NXO3SI1{OTlyOUO4PFQ>
SKMES1	M4HiRWN6fG:2b4jpZ{BCe3OjeR?=		MnTOO\|IhcA>?	Mn7oSG1UVw>?	NUO3W4Z3UUN3ME2yMlQzKM7:TR?=	MkHHNVkxQTN6OES=
S2	M1HJXWtqdmG\|ZTDBd5NigQ>?	M2TzT\|AvOS1zMDFOwG0>	NFHMZWEyKGh?		MYLJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	MXKxPVMyPzR3MB?=
SHSY5Y	Mmm2T4lv[XOnIFHzd4F6	NWrtbJRROTBizszN	NHP0R2w1QCCq	M4\wXWROW09?	M2L1SGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	M1zielE6OzR2MUe1
SHSY5Y	MUjDfZRwfG:6aXOgRZN{[Xl?	MUOxNEDPxE1?	MoPXOFghcA>?	NX:zcIc5TE2VTx?=	M3TaZmlEPTB;MjFOwG0>	NIm4Z2QyQTN2NEG3OS=>
DMS114	NX[1VlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2[xRlQ5KGh?		NF7nUGdIUTVyPUKuPUDPxE1?	M2jYe\|E6PDF7MkC1
HBC5	NV3JPWRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYDxUItMPDhiaB?=		NF3YW\|lIUTVyPUG3JO69VQ>?	NILnZZAyQTRzOUKwOS=>
SNB78	NWTkcIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHHWV2k1QCCq		M2rFeGdKPTB;MU[g{txO	NX3T[FNROTl2MUmyNFU>
HeLa	M2C5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEDr[JM4OiCq	MoDNSG1UVw>?	NEPTNoFKSzVyPUCuOFYh\|ryP	M2DMdVE6PDRzOES2
BHK	MlixT4lv[XOnIFHzd4F6	NHnaUHY2KM7:TR?=	M3r3clI1KGh?	NHn2V2NFVVOR	NYD0b41SUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	NHXNVYEyQTl4Nke4PS=>
CFBE41o-	MVfLbY5ie2ViQYPzZZk>	NUnpb5RSPSEQvF2=	M2jPc\|ghcA>?	MXfEUXNQ	NUfhelQxUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=>	MkfhNVk6PjZ5OEm=
CFBE41o-	NVXFUop5U2mwYYPlJGF{e2G7	MlXVOUDPxE1?	NFvK[YY1KGh?	MWTEUXNQ	M17aV2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBt\X[nbB?=	NEXKNIMyQTl4Nke4PS=>
CFBE41o-	MX\LbY5ie2ViQYPzZZk>	NWnjeGVzOSEQvF2=	NG\hbWQyKGh?	M{W4WmROW09?	NE\pOIRKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gR2ZVWiCycn;0[YlvKGyndnXs	NV25ZWtIOTl7Nk[3PFk>
Primary bronchial epithelial cell	NFK4fpRMcW6jc3WgRZN{[Xl?	MlHXNUDPxE1?	NVPNN2xYOjRiaB?=	NGTlOXVFVVOR	NXix[lZyUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5iYYDpZ4FtKHO3cn\hZ4UhdG:lYXzpfoF1cW:w	NHLoTpkyQTl4Nke4PS=>
CFBE41o-	NX;qfZl4U2mwYYPlJGF{e2G7	NXTocZU6OSEQvF2=	M3jwbVUh\GG7cx?=	NEf1[YVFVVOR	MmLvTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrenH0bY9vKG:oIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4>	MmfmNVk6PjZ5OEm=
CFBE41o-	M4X1O2tqdmG\|ZTDBd5NigQ>?	MWKxJO69VQ>?	MVWyOEBp	M3;oNGROW09?	NVqwdW45UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBH\GWudHG1NFghS0[WUjDwdo91\WmwIITyZYZncWOtaX7n	NVnJO2lxOTl7Nk[3PFk>
CFBE41o-	MVfLbY5ie2ViQYPzZZk>	NIHaNnE2KM7:TR?=	M2fOUlI1KGh?	MWDEUXNQ	MlGyTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1?	NUfCcIprOTl7Nk[3PFk>
CFBE41o-	M3vTTmtqdmG\|ZTDBd5NigQ>?	NVPWcZNNPSEQvF2=	NEO2[IszPCCq	MWPEUXNQ	NVXZZ2ptUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{fGGkaXzpeJkhd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	NWLi[4t3OTl7Nk[3PFk>
CFBE41o-	MmW4T4lv[XOnIFHzd4F6	Mn3OOUDPxE1?	Ml7oNlQhcA>?	MmKzSG1UVw>?	NVHwUZJ2UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju	NWrNWHRqOTl7Nk[3PFk>
Primary bronchial epithelial cell	MULLbY5ie2ViQYPzZZk>	NIXYXJg2KM7:TR?=	M4TIO\|I1KGh?	NVmycXVVTE2VTx?=	M3zKO2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	MXKxPVk3Pjd6OR?=
Primary bronchial epithelial cell	NW\QTFh1U2mwYYPlJGF{e2G7	MnfTNUDPxE1?	NUfxRmE2QTZiaB?=	NEnWV5FFVVOR	M1\BemlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd4hwenRiY3nyZ5VqfCCldYLy[Y51ew>?	M2DtdVE6QTZ4N{i5
BxPC3	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYW3NkBp		NIjaPGxKSzVyPUKuO{DPxE1?	NHfreoozODF2M{e3PC=>
CAL27	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\EOoY4OiCq		MUTJR\|UxRTNwN{Kg{txO	NXfrNodoOjBzNEO3O\|g>
Capan1	NFHhZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmjDO\|IhcA>?		NYLZfJpGUUN3ME23MlMh\|ryP	NVPoZYQyOjBzNEO3O\|g>
HCC827	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4jq[\|czKGh?		NXHmbpR2UUN3ME2xMlgh\|ryP	MWmyNFE1Ozd5OB?=
LNCAP	NEHZRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnrSO\|IhcA>?		M{W1U2lEPTB;MD61PEDPxE1?	MkTpNlAyPDN5N{i=
NCI-H2122	M2fFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoL1O\|IhcA>?		NX7BNpA6UUN3ME23MlUh\|ryP	NXHyPWtiOjBzNEO3O\|g>
NCI-H358	NXjybW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M33l[VczKGh?		MYjJR\|UxRTJwNTFOwG0>	M1TCRlIxOTR\|N{e4
SCC15	NI[zbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUXB[JlrPzJiaB?=		MmfxTWM2OD1{LkS5JO69VQ>?	MYKyNFE1Ozd5OB?=
SCC25	NYK1bHNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYTqdI41PzJiaB?=		MXXJR\|UxRTFwOUOg{txO	MY[yNFE1Ozd5OB?=
SKHEP1	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV63NkBp		M4D3bmlEPTB;Mz60OkDPxE1?	NIfpfGkzODF2M{e3PC=>
BJ	NGryeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWS3fFM5OTByIN88US=>	MkLuOFghcA>?	Ml3oSG1UVw>?	M{TBUmdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	NUPBbHE3OjBzNEO4OFA>
MUF	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjvUW4yODBizszN	NY[0R5BFPDhiaB?=	NIr3bG5FVVOR	Mn[5S5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	NIrIemwzODF2M{i0NC=>
Caco-2	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfmbWpkOTByIN88US=>	M2jo[FQ5cA>?	MlTwSG1UVw>?	M2rGT2lEPTB;OD6xJO69VQ>?	MkmzNlAyPDN6NEC=
Caco-2	MUHLbY5ie2ViQYPzZZk>	NYPLZXAxPSEQvF2=	MlzvOEBp	MY\EUXNQ	NHi1XItKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9vKEmFNUCgc4YhOC5yM{eg{txO	MV2yNFE1Ozh2MB?=
Caco-2	M3u2WWtqdmG\|ZTDBd5NigQ>?	MojXNE4{OTZibl2geI8hOzFwNjFOwG0>	NFLrWHY1KGh?	NEDjWGJFVVOR	NEXrXZFGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	MofUNlAyPDN6NEC=
Caco-2	M3PSN2tqdmG\|ZTDBd5NigQ>?	NYDhV5AzOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	NIjwS5k1KGh?	M2jNR2ROW09?	MoXBSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN\|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0>	Mk\KNlAyPDN6NEC=
Caco-2	M2Px[GtqdmG\|ZTDBd5NigQ>?	M4rjWVYvOzJibl2geI8hPjN{IN88US=>	MVy0JIg>	MWnEUXNQ	M{jRNGV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNTD3bZRpKEmFNUCgc4YhOTJwNjFOwG0>	M4XUR\|IxOTR\|OESw
Caco-2	NHv2TXlMcW6jc3WgRZN{[Xl?	NUe3[\|IyPi5\|MjDuUUB1dyB4M{Kg{txO	MoKwOEBp	MWTEUXNQ	NWDoXlZKTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO3JJdqfGhiSVO1NEBw\iB2MTFOwG0>	NYHKVFZwOjBzNEO4OFA>
Caco-2	Mn3LT4lv[XOnIFHzd4F6	NEDiOYQxNjNzNjDuUUB1dyB\|MT62JO69VQ>?	NUXDdY1IPCCq	NV\idpk6TE2VTx?=	Mk\ZSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN4	MkjZNlAyPDN6NEC=
HepG2	NFjpSlRMcW6jc3WgRZN{[Xl?	Ml;SOUDPxE1?	M4HKRlZp	MkC2SG1UVw>?	Mm\rTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvci=>	MlPZNlAyPDN6NEC=
HepG2	MnfuT4lv[XOnIFHzd4F6	MoLNOUDPxE1?	M4DlTVZp	Mn3vSG1UVw>?	NGjUSIxKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIh6eGW{YXPleJlt[XSrb36=	NFvwSmMzODF2M{i0NC=>
HepG2	MmLXT4lv[XOnIFHzd4F6	NWnVXlc2PSEQvF2=	NXOyU49TPmh?	NI\wfmhFVVOR	NF\UVZdKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	M{nONVIxOTR\|OESw
HepG2	M13IemtqdmG\|ZTDBd5NigQ>?	NWXuVYF4PSEQvF2=	NWTpXWF[Pmh?	MXvEUXNQ	MnnMTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgTFMwUDRiaHnzeI9v\SCjY3X0fYxifGmxbh?=	MmfONlAyPDN6NEC=
COLO205	MkW2T4lv[XOnIFHzd4F6	NFi0cWcyOCEQvF2=	NEDhSZozPCCq	MUfEUXNQ	MWjJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	M1vUb\|IxPDVzM{e4
SCC4	MnLOT4lv[XOnIFHzd4F6	MVWxJO69VQ>?	NGXJSokzPGh?		M33ueWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjD0eYJ2dGmwIHHj[ZR6dGG2aX;u	MlvoNlA1PTJ{MkW=
SCC4	MU\LbY5ie2ViQYPzZZk>	M3fLZlEh\|ryP	NVz5b4p1OjSq		NWPXc2VzUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgZYNmfHmuYYTpc44>	MorRNlA1PTJ{MkW=
SCC4	NG\x[o9HfW6ldHnvckBCe3OjeR?=	MYqxJO69VQ>?	NV\hXGY{PSCvaX6=		Mom2RYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	NWiwN5pMOjB2NUKyNlU>
NB4	MnLUSpVv[3Srb36gRZN{[Xl?	NETCWpk2KM7:TR?=	M2e4TFI1KGh?	MmrvSG1UVw>?	MlLZR4VtdCCleXPs[UBienKnc4SgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPjeY12dGG2aX;uJIF1KHC{ZT3HNUBxcGG\|ZR?=	M3;QW\|IxPDlzNESw
NB4	Ml3pT4lv[XOnIFHzd4F6	Mn3oOUDPxE1?	M2r0NVI1KGh?	MVTEUXNQ	MXvJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPleJlt[XSnIIT1ZpVtcW5ibHX2[Yw>	MWCyNFQ6OTR2MB?=
NB4	NUnacY1KTnWwY4Tpc44hSXO\|YYm=	MkXNOUDPxE1?	MlfyNlQhcA>?	M1:wW2ROW09?	NGnheY1KdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44>	Mn2yNlA1QTF2NEC=
NB4	M1f0UmtqdmG\|ZTDBd5NigQ>?	MV[1JO69VQ>?	MUKyOEBp	NHPhOmVFVVOR	MWTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	NE\sbGIzODR7MUS0NC=>
NUGC3	M2XwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTOS2k2OD1{Lkm0JO69VQ>?	NX\GW4tnOjB6NUC5O\|E>
A549	M4\lSGZ2dmO2aX;uJGF{e2G7	M1TyXlUh\|ryP	NInNZlI{KGh?	NVH6UW1OTE2VTx?=	MorSTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	MYqyNFg2PTJyOB?=
HUT78	M3TrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LYOlczKGh?	NE\YS3VFVVOR	M2\XbmdKPTB;MD6zJO69VQ>?	NE\sbXIzODh6NEKwPC=>
U937	M{TsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LiVVczKGh?	NEnSTGVFVVOR	MnOzS2k2OD1yLkO5JO69VQ>?	MmrqNlA5QDR{MEi=
A431	M{DFSmN6fG:2b4jpZ{BCe3OjeR?=		NIq3W4M4OiCq		MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR\|UxKG:oIESuNkDPxE1?	MofQNlExQDB4Mkm=
A549	MonPR5l1d3SxeHnjJGF{e2G7		Mn33O\|IhcA>?		MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJI93\XKneIDy[ZN{cW6pIFjERWMhf2m2aDDJR\|UxKG:oIEGuPEDPxE1?	MmrwNlExQDB4Mkm=
CAL27	MmLzR5l1d3SxeHnjJGF{e2G7		Mlq2O\|IhcA>?		MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDRWwzPyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjCzMlIh\|ryP	MUKyNVA5ODZ{OR?=
HeLa	MVXDfZRwfG:6aXOgRZN{[Xl?		MX:3NkBp		NHzXWVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=	M4Lrd\|IyODhyNkK5
Sf21	M1O0OmtqdmG\|ZTDBd5NigQ>?		MljoN{Bp		MUnJcohq[mm2aX;uJI9nKE[uYXegeIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM5KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4zKM7:TR?=	NY[1b2dCOjFyOEC2Nlk>
SKBR3	M33xTGN6fG:2b4jpZ{BCe3OjeR?=		NX;we2lGPzJiaB?=		MkfqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?=	M{LnZVIyODhyNkK5
SKOV3	MmToR5l1d3SxeHnjJGF{e2G7		NVz3fI03PzJiaB?=		M3n4SGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvOiEQvF2=	NVPReoxuOjFyOEC2Nlk>
COR-L23	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHW5fmIyOCEQvF2=	NVfmUVZPPzJiaB?=	NUiyZpRmTE2VTx?=	M{HFOmdKPTB;MT6xJO69VQ>?	MYKyNVA5ODZ2Nx?=
DU145	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fTclExKM7:TR?=	NEjjOW04OiCq	M2S0N2ROW09?	MnThS2k2OD1zLkC1JO69VQ>?	Mln2NlExQDB4NEe=
LoVo	NYDoPYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXQNVAh\|ryP	M4\tV\|czKGh?	MYTEUXNQ	MkX4S2k2OD1zLkeg{txO	NVfEWVBtOjFyOEC2OFc>
MCR5-SV2	M3\xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDpOWNbOTBizszN	MWi3NkBp	NFvPTVdFVVOR	MXPHTVUxRTJwMTFOwG0>	MWqyNVA5ODZ2Nx?=
HCT116	MmnET4lv[XOnIFHzd4F6	MUmzNEDPxE1?	NH\OOFg{OCCq	Ml;XSG1UVw>?	MknyTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	NYK0XmZ{OjFyOEC2OFc>
HCT116	M2HSTGtqdmG\|ZTDBd5NigQ>?	NWrhUGI{OzBizszN	M2i4UVMxKGh?	NX\4flY2TE2VTx?=	NXLRVVZuUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	M3vOcFIyODhyNkS3
U937	NXHqVVd2U2mwYYPlJGF{e2G7	M1jjdFUh\|ryP	Mn23NlQhcA>?	MUXEUXNQ	NYnsdlMxUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m=	MXOyNVI6OjR7Mh?=
U937	MW\LbY5ie2ViQYPzZZk>	MnTZOUDPxE1?	NY\GWZh7OjRiaB?=	NVzmVZd4TE2VTx?=	NUjrN4J4UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	MnvVNlEzQTJ2OUK=
U937	NVTSNYl2U2mwYYPlJGF{e2G7	M2LqfFUh\|ryP	MmftNlQhcA>?	NXzOfYJETE2VTx?=	NH7nN3ZKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YheGGwLXHj[ZR6dGG2ZXSgbIl{fG:wZTDIOEBt\X[nbB?=	NWDpUXlXOjF{OUK0PVI>
U937	MYTLbY5ie2ViQYPzZZk>	NYHOO\|RCPSEQvF2=	MYCxOUBucW5?	NFi1XpBFVVOR	M2LvR2lvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIHzleoVt	M1TYe\|IyOjl{NEmy
A2780	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1vEWFk3KGh?	NXmw[Xl6TE2VTx?=	MWHJR\|UxRTFwNkKg{txO	NHvtVWozOTZ\|NESzNC=>
COLO205	NWTxVFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoLlPVYhcA>?	MVfEUXNQ	M4SzSmlEPTB;Mj6xNkDPxE1?	Mn3ENlE3OzR2M{C=
Hep3B	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUfzdJRPPDhiaB?=	Mn;rSG1UVw>?	NWLaN49RT0l3ME2xMlIyKM7:TR?=	M3XKbFIyPzF{MUS2
GM11272	Mn\ySpVv[3Srb36gRZN{[Xl?	M{mwflExOCCwTR?=	NWnaPHd7PzJiaB?=	M4C0TWROW09?	MYTS[YFkfGm4YYTpc44hd2ZiTXXDdFIhdXW2YX70JIV5eHKnc4Ppc44h[XRiMUCgeI8hOTByIH7N	Mo\hNlE5PDB5MU[=
CFBE41o	M33ZcmtqdmG\|ZTDBd5NigQ>?	MkXGOUDPxE1?		NHzHeW9FVVOR	MkS1SI94diC{ZXf1cIF1cW:wIH;mJGhFSUN5IHH0JFAvOiC2bzC1JJVO	MW[yNVk5PDl3OB?=
CFBE41o	MVjGeY5kfGmxbjDBd5NigQ>?	M1nITFEh\|ryP	M{jkUlI1KGh?	MYfEUXNQ	NHv0UI9T\XO2b4LheIlwdiCxZjDDSnRTKGSnbIThSlUxQCCvdYThcpQhfHKjZn\pZ4tqdmdidH:gZ4VtdCC\|dYLmZYNmKGG\|IHfsfYNw\m:{bYO=	MX6yNVk5PDl3OB?=
DU145	M3jvT2tqdmG\|ZTDBd5NigQ>?	NUD2NZVKOi53IN88US=>	MUeyOEBp	NWexdZRpTE2VTx?=	MUfJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOXejZkGgdJJwfGWrbjDlfJBz\XO\|aX;u	MoL0NlIzPjBzNk[=
DU145	M{LxfmtqdmG\|ZTDBd5NigQ>?	NHTKOpM2KM7:TR?=	NVzxWldSOjRiaB?=	NXTHbIJYTE2VTx?=	M4DmeWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh2IHHj[ZR6dGG2aX;u	M1XYc\|IzOjZyMU[2
DU145	NV3mTJJvU2mwYYPlJGF{e2G7	MVe1JO69VQ>?	MkDnNlQhcA>?	MlP3SG1UVw>?	NXPk[nF1UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSEOgbJlx\XKjY3X0fYxifGmxbh?=	NFLn[IczOjJ4MEG2Oi=>
786-0	NWi5WG5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTPOk4zKM7:TR?=	MYK3NkBp	NFPTVm5FVVOR	M4jCeGdKPTB;Mz6yJO69VQ>?	NXK2eYx1OjJ2M{W2Olk>
A498	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXmZWJ[Pi5{IN88US=>	Mn;oO\|IhcA>?	NUHuOII3TE2VTx?=	NHLCe\|BIUTVyPUGuOkDPxE1?	M2q2RVIzPDN3Nk[5
A549/ATCC	NIroPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLNb4c3NjJizszN	NF\3dnE4OiCq	M2rVZ2ROW09?	NVHXbpJST0l3ME2xMlYh\|ryP	MUKyNlQ{PTZ4OR?=
ACHN	NVfuSYlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVG2MlIh\|ryP	NWnWUFhPPzJiaB?=	NEGzPGhFVVOR	NWH6Z3d3T0l3ME2xMlMh\|ryP	MUGyNlQ{PTZ4OR?=
BT549	NXfPPJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M135dFYvOiEQvF2=	Mn3xO\|IhcA>?	M2DB[mROW09?	NFPPeIVIUTVyPUGuN{DPxE1?	MXyyNlQ{PTZ4OR?=
EKVX	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXu2MlIh\|ryP	NUHOdIQ5PzJiaB?=	MlfWSG1UVw>?	M{PRe2dKPTB;MT6zJO69VQ>?	NU\5U\|BqOjJ2M{W2Olk>
HCT15	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TiV\|YvOiEQvF2=	MoC2O\|IhcA>?	NUXrTGRtTE2VTx?=	NIfBcFdIUTVyPUKuOUDPxE1?	NX;SeHhLOjJ2M{W2Olk>
HOP92	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYm2MlIh\|ryP	MYW3NkBp	NHqzTXJFVVOR	M2PsXWdKPTB;NDFOwG0>	MlLrNlI1OzV4Nkm=
IGROV1	NIHpbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7M[ppFPi5{IN88US=>	NVjVN4d4PzJiaB?=	NEGybJpFVVOR	MoT6S2k2OD1zLkOg{txO	NXz1bZppOjJ2M{W2Olk>
LOXIMVI	MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1ezflYvOiEQvF2=	M{S4OlczKGh?	NYDVe254TE2VTx?=	MmXXS2k2OD1zIN88US=>	NETpRmYzOjR\|NU[2PS=>
M14	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfYOk4zKM7:TR?=	NGrNTJo4OiCq	NF3sbIFFVVOR	MlO4S2k2OD1zLkOg{txO	NECwdIMzOjR\|NU[2PS=>
MALME-3M	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXTN21LPi5{IN88US=>	MnTVO\|IhcA>?	MljjSG1UVw>?	NVfOPJp6T0l3ME2wMlMzKM7:TR?=	NIXSNZAzOjR\|NU[2PS=>
MCF10A	NEXFVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjx[3lSPi5{IN88US=>	NHPkVVM1QCCq	M2DoWWROW09?	MkHhS2k2OD17Lk[g{txO	NVOyTGRuOjJ2M{W2Olk>
MDA-MB-435	NFnUfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv0UpE3NjJizszN	MlzaO\|IhcA>?	M2LPXWROW09?	NIC0dIFIUTVyPUCuOUDPxE1?	MmD2NlI1OzV4Nkm=
MDA-MB-468	M1PLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13GelYvOiEQvF2=	NIO1SGk4OiCq	NYPmcFBwTE2VTx?=	MYjHTVUxRTBwNkOg{txO	NILnZVYzOjR\|NU[2PS=>
MOLT4	NWH5OpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWK2MlIh\|ryP	MUK3NkBp	NX;LSlRVTE2VTx?=	MVfHTVUxRTBwNDFOwG0>	M1:3fVIzPDN3Nk[5
NCI-ADR-RES	NHfvfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL5Sow5Pi5{IN88US=>	MV63NkBp	MkTsSG1UVw>?	NGXBWWRIUTVyPUCuNVYh\|ryP	MYiyNlQ{PTZ4OR?=
NCI-H23	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvndXRFPi5{IN88US=>	MmLxO\|IhcA>?	MYXEUXNQ	M{nGW2dKPTB;MTFOwG0>	NVvB[mhMOjJ2M{W2Olk>
NCI-H322M	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PxNFYvOiEQvF2=	NIS2b5I4OiCq	NV;EfW9LTE2VTx?=	NIn6V4FIUTVyPUCuO\|kh\|ryP	Mny4NlI1OzV4Nkm=
NCI-H460	M3TjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[1NlYvOiEQvF2=	NG\yNGE4OiCq	M2G5WWROW09?	M{HyRmdKPTB;MD63PUDPxE1?	Mn7WNlI1OzV4Nkm=
NCI-H522	NIrjd\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEm1dWY3NjJizszN	M2nLXlczKGh?	MYrEUXNQ	M4S4WWdKPTB;MD61JO69VQ>?	MoHZNlI1OzV4Nkm=
OVCAR3	M2q4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;MW\|YvOiEQvF2=	NFu4WFY4OiCq	NFHySo9FVVOR	M4Ll[GdKPTB;MT6zJO69VQ>?	NYLkVm5zOjJ2M{W2Olk>
OVCAR4	M{PpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzHOk4zKM7:TR?=	Mo\HO\|IhcA>?	MVLEUXNQ	NULWSYo6T0l3ME20JO69VQ>?	MUmyNlQ{PTZ4OR?=
OVCAR5	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPaOk4zKM7:TR?=	NHPyV2E4OiCq	NW\NclU3TE2VTx?=	MYfHTVUxRTBwN{mg{txO	MWWyNlQ{PTZ4OR?=
OVCAR8	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[2MlIh\|ryP	NFTUT5c4OiCq	NGjvSJpFVVOR	MYXHTVUxRTBwNTFOwG0>	M2\YW\|IzPDN3Nk[5
RXF393	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXW2MlIh\|ryP	MVK3NkBp	NU\IfWtJTE2VTx?=	M3nYUGdKPTB;MT6zJO69VQ>?	Mk[3NlI1OzV4Nkm=
SF268	NWDHVpR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYi2OlU6Pi5{IN88US=>	M3iwUVczKGh?	NYPXOHNmTE2VTx?=	NFPqfnVIUTVyPUGuOkDPxE1?	M3H1TFIzPDN3Nk[5
SF295	M2jUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj3SmZJPi5{IN88US=>	NGDxblA4OiCq	NWH5[GdGTE2VTx?=	MWDHTVUxRTFwNjFOwG0>	NFrrXnYzOjR\|NU[2PS=>
SF539	M2HQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjaPGQ3NjJizszN	NFLYWpg4OiCq	M4DObmROW09?	NIrtZotIUTVyPUKg{txO	Mk\1NlI1OzV4Nkm=
SK-MEL-2	NIrtSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLGOk4zKM7:TR?=	NIPiNmg4OiCq	NVXsd2lvTE2VTx?=	MnfXS2k2OD1zLkOg{txO	MUmyNlQ{PTZ4OR?=
SK-MEL-28	M4mxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[1Ok4zKM7:TR?=	NGLpWVc4OiCq	NXzY[llsTE2VTx?=	M4PiPGdKPTB;MTFOwG0>	NInnTlczOjR\|NU[2PS=>
SK-MEL-5	M2DH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrqUINJPi5{IN88US=>	NXTTWphpPzJiaB?=	MVnEUXNQ	NGezNJlIUTVyPUCuOlMh\|ryP	Mke5NlI1OzV4Nkm=
SKOV3	NFfKOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzFOk4zKM7:TR?=	NID3SXk4OiCq	M173TmROW09?	MYHHTVUxRTFizszN	NVfTV4NZOjJ2M{W2Olk>
SN12C	NVfBbY9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLNOk4zKM7:TR?=	M3;KSVczKGh?	NGfqWZRFVVOR	M4jqeWdKPTB;MjFOwG0>	NVXhbGNPOjJ2M{W2Olk>
SNB19	NVLlclA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PD[VYvOiEQvF2=	NFfkdo84OiCq	M4jjO2ROW09?	Mn;6S2k2OD1yLk[zJO69VQ>?	NIDidZIzOjR\|NU[2PS=>
SNB75	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmT6Ok4zKM7:TR?=	NEnZPWc4OiCq	NH\KU4lFVVOR	NHewPZJIUTVyPUCuO\|kh\|ryP	NVfJUGRtOjJ2M{W2Olk>
SR	NHfwTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXPZmc3NjJizszN	MVu3NkBp	NETpflFFVVOR	NVu1PZVkT0l3ME2wMlQh\|ryP	M4W2UlIzPDN3Nk[5
T47D	MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDxfG43NjJizszN	MVO3NkBp	Ml61SG1UVw>?	MWHHTVUxRTBwNTFOwG0>	NFjXN\|gzOjR\|NU[2PS=>
TK10	NV7yVXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;KOk4zKM7:TR?=	NEe5NWM4OiCq	M37ZemROW09?	M{H6R2dKPTB;MD62N{DPxE1?	NFexNJQzOjR\|NU[2PS=>
UACC257	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUm2MlIh\|ryP	MVS3NkBp	NI\MNFVFVVOR	MmPES2k2OD1yLkWg{txO	MV6yNlQ{PTZ4OR?=
UACC62	M{DF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXG2MlIh\|ryP	MVy3NkBp	Mm\pSG1UVw>?	NWrhT4hwT0l3ME2wMlQh\|ryP	Mlm5NlI1OzV4Nkm=
UO31	NXHlVG1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHac\|dxPi5{IN88US=>	NVvhVIFCPzJiaB?=	Mn3xSG1UVw>?	NGnzSYZIUTVyPUCuOUDPxE1?	NXOzSZFsOjJ2M{W2Olk>
Hep3B	NVq3THR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1TGflQ5KGh?	NI\0NJdFVVOR	M2jkVWdKPTB;MD62PUDPxE1?	NVTsOVZwOjJ2M{m4OlM>
BE(2)-C	NUnIZY5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn64O\|IhcA>?	M3e0ZmROW09?	MYHJR\|cxRTJizszN	NVK1fHFuOjJ7M{KzNVY>
Bel7402	NHzuSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX63NkBp	NH3lWYdFVVOR	MlfVS2k6OD1zNzFOwG0>	MlL2NlMxPjF\|N{[=
Bel7404	NVfWNIcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUm0[WpWPzJiaB?=	MWXEUXNQ	NFvne\|FIUTlyPUG4JO69VQ>?	NVfsUHc1OjNyNkGzO\|Y>
BGC823	M2qwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHnnfI04OiCq	M3\hNWROW09?	M1;JdGdKQTB;Nz61JO69VQ>?	M4TESlI{ODZzM{e2
MGC803	NYnX[2k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX3vRlhlPzJiaB?=	M4jCVmROW09?	MYrHTVkxRTFyLkig{txO	MXSyN\|A3OTN5Nh?=
SGC7901	MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFPUeXQ4OiCq	MWTEUXNQ	MXrHTVkxRTlwNDFOwG0>	NWTrS2tFOjNyNkGzO\|Y>
SKHEP1	NVnnO2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{Pu[lczKGh?	NYnZS4R7TE2VTx?=	NWXE[GpST0l7ME2xO{DPxE1?	NVvBZVNmOjNyNkGzO\|Y>
SMMC7721	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4\MNVczKGh?	M2PjSGROW09?	MnzuS2k6OD1{MDFOwG0>	M3TlO\|I{ODZzM{e2
NUGC3	NEDKXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrsNVAh\|ryP			NHHkNlJIUT1{Lkm0JO69VQ>?	NEfUZ4czOzF4M{OzNi=>
A2780 CisR	NWDROWt6U2mwYYPlJGF{e2G7		NWrRXWZXOThiaB?=		MmDSTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkS0JO69VQ>?	NH3GZ3IzOzJ3Mk[wNy=>
CAL27 sens	MYPLbY5ie2ViQYPzZZk>		MkHmNVghcA>?		NYrIUHc6UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?=	M1TmbVI{OjV{NkCz
CAL27 CisR	MlXpT4lv[XOnIFHzd4F6		M2LCbVE5KGh?		NXPGSJFZUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	M4DsSVI{OjV{NkCz
KYSE-510 CisR	NEe3d5ZMcW6jc3WgRZN{[Xl?		M3j6PVE5KGh?		M1rhZ2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61PUDPxE1?	NUW5NoxmOjN{NUK2NFM>
KYSE-510 sens	NFfTRW9McW6jc3WgRZN{[Xl?		M3PQPVE5KGh?		MWPJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNzFOwG0>	NXHDOJdNOjN{NUK2NFM>
MDA-MB-231 sens	M4nFdmtqdmG\|ZTDBd5NigQ>?		M2TNZ\|E5KGh?		M1XWN2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	MkfMNlMzPTJ4MEO=
MDA-MB-231 CisR	M4LBW2tqdmG\|ZTDBd5NigQ>?		MXqxPEBp		MYTJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	M{XmTlI{OjV{NkCz
ES2	NGDiUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF76PGY1QCCq	MYfEUXNQ	MVfJR\|UxRTF{Lkeg{txO	M1zOWVI{PDl\|NES5
MDA-MB-231	M3jtfmtqdmG\|ZTDBd5NigQ>?	NFmzV20yOCEQvF2=	MnrjN\|AhdWmw	MUPEUXNQ	NGHmWoNKdmirYnn0bY9vKG:oIFjERWMz[Q>?	M{L2VlI{PDl\|NES5
MDA-MB-231	NXfOeo5FU2mwYYPlJGF{e2G7	MYixJO69VQ>?	MX[yOEBp	MYnEUXNQ	MVnJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGGlZYT5cIF1cW:wIHzleoVteyCxZjD0eYJ2dGmw	NVfDS\|h1OjN2OUO0OFk>
HS68	M3raT2N6fG:2b4jpZ{BCe3OjeR?=	NHnCOFEyOCEQvF2=	NVvISpJnPzJiaB?=	NXjNWoxUTE2VTx?=	M131TmlEPTB;ND62JO69VQ>?	M4PXc\|I{PTdyNUSy
MEF	NWO5SJVOS3m2b4TvfIlkKEG\|c3H5	MWKxNEDPxE1?	M1TQdFczKGh?	NYj3fGRETE2VTx?=	MlzxTWM2OD12LkSg{txO	NVPCfXpqOjN3N{C1OFI>
BGC823	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHzPWHBFVVOR	M2TycGdKPTB;Mz6wPUDPxE1?	M4LCfFI{PjBzN{C2
High5	NEDNVFhMcW6jc3WgRZN{[Xl?		M1viW\|I1KGh?		M3vRXWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Yhf2m2aDDJR\|UxKG:oIECuNFkh\|ryP	MXWyN\|YxOjV{Mx?=
High5	M2XFZWtqdmG\|ZTDBd5NigQ>?		NHexe\|AzPCCq		NYjnN41[UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4yOiEQvF2=	NF\lWmMzOzZyMkWyNy=>
High5	NGnCZ25McW6jc3WgRZN{[Xl?		NV3KW2h1OjRiaB?=		NInXWmdKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KHerdHigTWM2OCCxZjCwMlE4KM7:TR?=	MYqyN\|YxOjV{Mx?=
A549	NFvKeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFfnSY1FVVOR	NHjqPWxKSzVyPUGuNFc6KM7:TR?=	NWKxTnVWOjN4NESyNVA>
HCT116	NWrkOZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2HSRmROW09?	NXvvSm5JUUN3ME2wMlc2PyEQvF2=	NYqwcIdCOjN4NESyNVA>
K562	NGLUVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml63SG1UVw>?	M1jufmlEPTB;MD62OFUh\|ryP	NYXPfnEyOjN4NESyNVA>
GBC-SD	NGKzOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX4OUDPxE1?	MXK3NkBp	M2nHfmROW09?	MVrJR\|UxRTF2Lkig{txO	M3\mdlI{PzB5Mk[w
HGC27	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXZPJM2KM7:TR?=	NV;TVHE1PzJiaB?=	MlL0SG1UVw>?	NVPES5hwUUN3ME21MlQh\|ryP	NUXtdm15OjN5MEeyOlA>
HL60	NFrlZYlMcW6jc3WgRZN{[Xl?	M3P6VlUh\|ryP	NIPlcW8zPCCq	M1\0NWROW09?	Mki4TY5pcWKrdHnvckBw\iCKRFHD	NUfydWEzOjN5MEeyOlA>
Vero	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUH3d3pEPzJiaB?=	Ml;qSG1UVw>?	NU[3[nc3UUN3ME2wMlkh\|ryP	MVOyN\|c5PjR3Mh?=
NCI60	MUfDfZRwfG:6aXOgRZN{[Xl?		M1i3blQ5KGh?	NYjWbYhJTE2VTx?=	MkHzS2k:OC53MzFOwG0>	MlLLNlQxOTV\|Mke=
SW620	MnXjR5l1d3SxeHnjJGF{e2G7		MVi0PEBp	NEjkbHhFVVOR	NXzJS4VQT0l;MD61OEDPxE1?	MX6yOFAyPTN{Nx?=
U251	MoHRR5l1d3SxeHnjJGF{e2G7		NHTH[3M1QCCq	MoT4SG1UVw>?	NHrYNIFIUT1zLkWzJO69VQ>?	NYDzbm9mOjRyMUWzNlc>
KM12	MVzDfZRwfG:6aXOgRZN{[Xl?		NVvPPWNSPDhiaB?=	M363[WROW09?	NGTXZVBIUT1zLki4JO69VQ>?	NIKycY8zPDBzNUOyOy=>
Hs578T	MWjDfZRwfG:6aXOgRZN{[Xl?		M3zoTVQ5KGh?	M1fBdWROW09?	NXu0N4N[T0l;ND64N{DPxE1?	Mn3jNlQxOTV\|Mke=
MDA-MB-231	M{i1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXja[ZI6PDhiaB?=		NIf2[2xKSzVyPUCuNVYh\|ryP	Mn6wNlQxQTVyMU[=
MCF7	MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIXBfFA1QCCq		MnS4S2k:OC52NTFOwG0>	MYOyOFEyQTV3NR?=
MDA-MB-435	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnfMOFghcA>?		M2faSWdKRTBwOEig{txO	NYTJVoxKOjRzMUm1OVU>
AsPC1	NGDsTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnEZYE{OCEQvF2=	NEDzZY01QCCq	M124WGROW09?	MWPJR\|UxRTNwNk[g{txO	MW[yOFE5PTN5OB?=
Jurkat E6.1	NXzneJJvU2mwYYPlJGF{e2G7		NH\F[2ozKGh?	NFHuR4JFVVOR	NYHCZpBnUW6qaXLpeIlwdiCxZjDISGFEPCC5aYToJGlEPTBib3[gNE4xPCEQvF2=	Mm\lNlQzPjF6NkK=
KG1	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HwR\|Q5KGh?		Mn;mTWM2OD1zLkG1JO69VQ>?	M1z4dlI1PTJ3MECz
HEL	M4D3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFnERVE1QCCq	MV3EUXNQ	NYjPSIg3UUN3ME2wMlQ6KM7:TR?=	NYD1XFdZOjR4OUSwOVU>
HSC3	NGq4UZJEgXSxdH;4bYMhSXO\|YYm=		Mmn1NVIhcA>?	MkH6SG1UVw>?	NETqeoVKSzVyPUCuO\|Eh\|ryP	MnfNNlQ4PjZ3NkC=
HT-29	Mkj1R5l1d3SxeHnjJGF{e2G7		MUexNkBp	M2PoZWROW09?	MXzJR\|UxRTBwN{Kg{txO	NGTCXIgzPDd4NkW2NC=>
KB	NITDNXREgXSxdH;4bYMhSXO\|YYm=		Mlq3NVIhcA>?	NXjldHBOTE2VTx?=	M3zNcmlEPTB;MD63OUDPxE1?	M4\4WlI1PzZ4NU[w
H460	NFL3TotEgXSxdH;4bYMhSXO\|YYm=		MXuxNkBp	NWfiUI9ZTE2VTx?=	NF[0SpZKSzVyPUCuPFIh\|ryP	Mn7sNlQ4PjZ3NkC=
MONE1	NGDpZ2hEgXSxdH;4bYMhSXO\|YYm=		MXSxNkBp	NFK5V2ZFVVOR	NF;wdlhKSzVyPUGuNVgh\|ryP	M2LsbFI1PzZ4NU[w
MKN45	NUPuUJoxS3m2b4TvfIlkKEG\|c3H5		MYCxNkBp	MoDDSG1UVw>?	NHPMeo5KSzVyPUGuNlUh\|ryP	MkDKNlQ4PjZ3NkC=
TSGH	NWjld\|dCS3m2b4TvfIlkKEG\|c3H5		NX;3bHd{OTJiaB?=	NW\5[\|MzTE2VTx?=	M2DXOmlEPTB;Mj6wPUDPxE1?	MUCyOFc3PjV4MB?=
HL60	NFPTc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVO3NkBp	M4nqT2ROW09?	NX64WZljT0l3ME2wMlk{KM7:TR?=	M1rmVFI1QTByNUCw
HEK293	NUDneG93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVi3NkBp	Mm\wSG1UVw>?	Ml\ZS2k2OD1zMzFOwG0>	MlmxNlQ6ODB3MEC=
Jurkat	NELXOlZEgXSxdH;4bYMhSXO\|YYm=	NVTyeHUzOTByIN88US=>	MXS3NkBp		NXvCOm9pT0l3ME2wMlkh\|ryP	M3TrWVI1QTByN{Sz
GM15850	NUTDR5RlU2mwYYPlJGF{e2G7	MmLsNk42KM7:TR?=	NHXlemw6PiCq	MUPEUXNQ	Ml7U[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NGDzUoMyPjl{MUO2Oy=>
GM15850	NWf5[WVHU2mwYYPlJGF{e2G7	MV:yMlUh\|ryP	MnnJPVYhcA>?	M2TKfmROW09?	NX;nV2V3\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDViYXPleJlt[XSrb36gc4YhTliQIHflcoU>	MWOxOlkzOTN4Nx?=
GM15850	MVzLbY5ie2ViQYPzZZk>	NVLDTItXOi53IN88US=>	NEmyOlY6PiCq	NHfPcmFFVVOR	NE\vUohld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTJiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NV3oTFM{OTZ7MkGzOlc>
GM15850	M4PHZmtqdmG\|ZTDBd5NigQ>?	MlvCNk42KM7:TR?=	NH[w[Gw6PiCq	MXnEUXNQ	NHzpbmNld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NV\2UphjOTZ7MkGzOlc>
GM15850	MonWT4lv[XOnIFHzd4F6	MWiyMlUh\|ryP	NVzTOIxsQTZiaB?=	M1zyUGROW09?	M2nvVoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA5KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NVHFVJBkOTZ7MkGzOlc>
GM15850	M3jtd2tqdmG\|ZTDBd5NigQ>?	NYrIVYNHOi53IN88US=>	MUO5OkBp	MlH0SG1UVw>?	NU\LcVl5\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF4IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	NHXxW4cyPjl{MUO2Oy=>
GM15850	M4DS[2Z2dmO2aX;uJGF{e2G7	MmezOUDPxE1?	Mm\3NVIhcA>?	MVfEUXNQ	NIDGTY1p[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	NX;5cnRbOTZ7MkGzOlc>
U937	MX7LbY5ie2ViQYPzZZk>	MUm1JO69VQ>?	M2jmVFI1KGh?	NVexSI0xTE2VTx?=	M4T1UYhieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	MYCxO\|Q1Pzd3MB?=
U937	NFL2OJdMcW6jc3WgRZN{[Xl?	NIm3c5QyKM7:TR?=	NEPEWmMzPCCq	MlnaSG1UVw>?	NVT0bXhXcGG\|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	NGWyWIQyPzR2N{e1NC=>
PANC1	MVnGeY5kfGmxbjDBd5NigQ>?	M2HxdFEh\|ryP	NEDQVpMzPCCq		NIjBSmhld2W\|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	MoeyNVc2QDh5NES=
PANC1	M1zCS2Z2dmO2aX;uJGF{e2G7	NYDndXdCOSEQvF2=	MmnIOFghKGh?		NVT0d5pn\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	M1fvXlE4PTh6N{S0
Caco-2	MV7GeY5kfGmxbjDBd5NigQ>?	NX7BdZU{PSEQvF2=	M{nmTFI1KGh?	MX3EUXNQ	M2XmU4Rw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>?	NFr6WIIzODF2M{i0NC=>
SCC4	MnfvSpVv[3Srb36gRZN{[Xl?	MnjBNUDPxE1?	NW\2UVVrOTBibXnu	NWrxcGlUTE2VTx?=	MX7oZZMhdm9iYXfvcol{fCCjY4Tpeol1gSCjdDDWSHIh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGN[WDJ2IHflcoUh\XiycnXzd4lwdg>?	NEizPW0zODR3MkKyOS=>
A549	NUPXelRMTnWwY4Tpc44hSXO\|YYm=	MX21JO69VQ>?	M2j0[\|MhcA>?	NWrEbFh[TE2VTx?=	MUHkc4V{KG6xdDDpcoR2[2ViYYX0c5Bp[We7IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	MVOyNFg2PTJyOB?=
HCT116	MWnLbY5ie2ViQYPzZZk>	NGexNY8xNjNizszN	NVjs[nRuOzBiaB?=	MnLoSG1UVw>?	M2ThZ4Rw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=>	MmDTNlExQDB4NEe=
HepG2	NVrzVoh4TnWwY4Tpc44hSXO\|YYm=	M4TtSFExKM7:TR?=	MWGyOEBp	MXXEUXNQ	Mnvp[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?=	NEDuR4YzOTV2OEW4Ni=>
GM11272	M2j5WGZ2dmO2aX;uJGF{e2G7	NWWz[2l5OC5zIN88US=>	NVnwRmxGPzJiaB?=	M3vqWWROW09?	NWnzXHZM\G:nczDuc5QhemWjY4TpeoF1\SCPZVPwNkBufXSjboSg[ZhxemW\|c3nvci=>	NGH6cWwzOTh2MEexOi=>
MDA-MB-231	NVXIe3BQU2mwYYPlJGF{e2G7	NHK3VnIyOCEQvF2=	MXy1JI1qdg>?	M3r6Z2ROW09?	MorI[I9meyCwb4SgbY5pcWKrdDDISGFEOmF?	NHjxTXEzOzR7M{S0PS=>
MDA-MB-231	MWDLbY5ie2ViQYPzZZk>	NFS3R4kyKM7:TR?=	MmPYNlQhcA>?	MlHCSG1UVw>?	M2T3RoRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>	M2ryN\|I{PDl\|NES5
K562	NHyzemJMcW6jc3WgRZN{[Xl?				NFfCUXVld2W\|IH7veEBqdmirYnn0JGhFSUN?	NWXsbppoOjN3OUGxNVE>
Jurkat	MmftR5l1d3SxeHnjJGF{e2G7	M1jmSFIxKM7:TR?=	MUm3NkBp	Ml3ZSG1UVw>?	MXruc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36=	MVSyOFMxPDN2OB?=
HCT116	MYPBdI9xfG:\|aYOgRZN{[Xl?	M{jVO\|Mh\|ryP	NYWxW29[OjRiaB?=	NGTldJBFVVOR	NV;BTm5K\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?=	M3rRU\|I1PzZ4NU[w
KASUMI-1	M4ewWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTl7LkG3JI5O	MnHXV2FPT0WU
KARPAS-45	MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfnTWM2OD1zN{OuPFkhdk1?	MXrTRW5ITVJ?
BHT-101	NVzQXmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfoXnREUUN3ME2yOFQvOThibl2=	MnfSV2FPT0WU
H9	M2DId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUW0ZYNSUUN3ME2yOVUvODRibl2=	MV7TRW5ITVJ?
PA-1	NHnjSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC4bpBKSzVyPUK4Ok4zPiCwTR?=	MYnTRW5ITVJ?
NEC8	M3S2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVqyZYxHUUN3ME2yPFkvOzhibl2=	MXHTRW5ITVJ?
MHH-PREB-1	NUDnSpBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJ7ND61N{BvVQ>?	M1vUR3NCVkeHUh?=
NB7	NYTr[IxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTN2NT63OEBvVQ>?	M1\pSXNCVkeHUh?=
A3-KAW	M3zGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTRyMD61PUBvVQ>?	NWLjU2hiW0GQR1XS
NB69	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInZRXVKSzVyPUSxNU44OSCwTR?=	MWfTRW5ITVJ?
EoL-1-cell	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HmW2lEPTB;NEW0NlUhdk1?	MUPTRW5ITVJ?
CHP-212	NX32WXlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTR3Nz61N{BvVQ>?	NV2wfIJFW0GQR1XS
C2BBe1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnFcpFKSzVyPUS3Nk4yQSCwTR?=	MXPTRW5ITVJ?
697	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PYcmlEPTB;NEezMlQyKG6P	MnK1V2FPT0WU
BCPAP	M4jid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV30dGd2UUN3ME21NFEvPDJibl2=	NFvHPHBUSU6JRWK=
L-363	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnqcIFKSzVyPUWwN{4yKG6P	NXzRbpBHW0GQR1XS
ES8	M2ewTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTV{Mz61N{BvVQ>?	M2f0c3NCVkeHUh?=
BE-13	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXSTWM2OD13Mk[uPVYhdk1?	MmLpV2FPT0WU
CTB-1	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLzeIFKSzVyPUWzO{46OiCwTR?=	MmrFV2FPT0WU
HD-MY-Z	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTV\|OD6xN{BvVQ>?	MnLUV2FPT0WU
NKM-1	NXKyOodTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHoW4hKSzVyPUW0OE4zPyCwTR?=	M1jrWXNCVkeHUh?=
NCI-H720	M1PQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zGOmlEPTB;NU[wMlE5KG6P	M1rsW3NCVkeHUh?=
KY821	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTV4Mz6yOUBvVQ>?	NGradpFUSU6JRWK=
OVCAR-5	M3XOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\QdmhKSzVyPUW3Ok4yOSCwTR?=	MlPUV2FPT0WU
CTV-1	NY\Sc29xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnmXY9JUUN3ME21PFEvPTZibl2=	NIjBd4xUSU6JRWK=
P12-ICHIKAWA	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo[2TWM2OD13OU[uOVEhdk1?	MYPTRW5ITVJ?
DB	M4W4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fnc2lEPTB;NUm4MlU4KG6P	NGrWeHRUSU6JRWK=
CHL-1	NGjXbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4G4ZWlEPTB;NkSyMlA5KG6P	MlHLV2FPT0WU
A4-Fuk	NX;u[I1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne3TWM2OD14NESuPVEhdk1?	MlrkV2FPT0WU
MV-4-11	NHG2NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXe1NWhsUUN3ME22OVkvOSCwTR?=	MVHTRW5ITVJ?
RPMI-8226	M3XSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnuTGx5UUN3ME22O\|gvOThibl2=	MlrMV2FPT0WU
NB14	M{\NO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXSTWM2OD14OU[uPVUhdk1?	Ml\nV2FPT0WU
DOHH-2	M1zS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTPcYp5UUN3ME23NFYvPjhibl2=	NGfDblBUSU6JRWK=
D-423MG	NF2xTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D4d2lEPTB;N{C2Mlg6KG6P	MWXTRW5ITVJ?
D-283MED	NF7veIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPGTWM2OD15MUSuNVQhdk1?	NWS0XWw4W0GQR1XS
ES1	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\VTWM2OD15MkSuOEBvVQ>?	MX7TRW5ITVJ?
GOTO	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXG4fFN6UUN3ME23NlkvOTJibl2=	MV7TRW5ITVJ?
NCI-H209	M{G3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGW4Tm5KSzVyPUeyPU46KG6P	NWOw[m5IW0GQR1XS
MOLT-13	NVHtPYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\pTWM2OD15M{iuPVghdk1?	NEXLTXJUSU6JRWK=
ATN-1	M1HId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTd2MD6yPEBvVQ>?	MnXJV2FPT0WU
DU-4475	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHB[XM5UUN3ME23OVEvQTFibl2=	NXq2XnA1W0GQR1XS
NB10	Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFP1W3lKSzVyPUe1NU46OiCwTR?=	NHPLfYZUSU6JRWK=
KG-1	NV3OSVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPLTWM2OD15N{WuOFUhdk1?	MnjoV2FPT0WU
MOLT-4	M1vHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXXTWM2OD15OEeuOFYhdk1?	MoO4V2FPT0WU
TE-1	M2PKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTd7MT6xJI5O	MoHDV2FPT0WU
SBC-1	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTd7Mz64OEBvVQ>?	NVqzfVN1W0GQR1XS
HEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH24[HlKSzVyPUiwOk4xQCCwTR?=	NUTEeXVzW0GQR1XS
SK-MEL-2	NUH5[YxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PvS2lEPTB;OEC5MlQ1KG6P	NVrkT4p[W0GQR1XS
KU812	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnQTWM2OD16MUOuNUBvVQ>?	Mn;kV2FPT0WU
RPMI-8866	M3vSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjx[Y5KSzVyPUixN{43PyCwTR?=	MmDRV2FPT0WU
ALL-PO	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn5fJpKSzVyPUixOE43PiCwTR?=	NGXoO4NUSU6JRWK=
LU-139	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3q2NmlEPTB;OEKyMlg3KG6P	MlHqV2FPT0WU
RS4-11	NVPWTIJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFu0W\|BKSzVyPUizNk41PSCwTR?=	NG\NflRUSU6JRWK=
EW-18	M3X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPofmlwUUN3ME24N\|IvQTZibl2=	NX:1W2h2W0GQR1XS
P30-OHK	M3\wVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTh\|NT63JI5O	NHfOUmFUSU6JRWK=
D-566MG	NXf2V5pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPpV3dKSzVyPUizPE43OiCwTR?=	NF\6[4lUSU6JRWK=
HSC-4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4roV2lEPTB;OES2MlUyKG6P	NWfxRXJMW0GQR1XS
QIMR-WIL	M1OyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fPTWlEPTB;OE[yMlA{KG6P	M4PvRXNCVkeHUh?=
SW954	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37xR2lEPTB;OE[zMlE3KG6P	M4jYZ3NCVkeHUh?=
HGC-27	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrRbnlnUUN3ME24O\|IvOzRibl2=	NXTCUXd[W0GQR1XS
HH	NWf2RXg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVn2V3lSUUN3ME24PVQvOTJibl2=	NE\jfm1USU6JRWK=
KE-37	NXrEW3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TGeWlEPTB;OEm0MlYzKG6P	MnW3V2FPT0WU
SK-N-DZ	M4fWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTlyMD60N{BvVQ>?	MonlV2FPT0WU
J-RT3-T3-5	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUj6[ppkUUN3ME25NVAvPDlibl2=	MXzTRW5ITVJ?
A427	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTl{MD64OEBvVQ>?	NF\VR\|hUSU6JRWK=
ECC10	NF;Sfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fEW2lEPTB;OUS1Mlg4KG6P	MX;TRW5ITVJ?
EW-1	NYL1SZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlGxTWM2OD17NEeuNlYhdk1?	NYDs[3NVW0GQR1XS
MIA-PaCa-2	M{PZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\0O\|hRUUN3ME25OFkvOTJibl2=	NEjiRWxUSU6JRWK=
HCC2218	M2fNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkT2TWM2OD17NUiuOFghdk1?	NEDJdFlUSU6JRWK=
HAL-01	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LtSGlEPTB;OU[4MlA1KG6P	M4K0XHNCVkeHUh?=
RD	NFvocpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TuN2lEPTB;OUe0MlQ2KG6P	NWj1d25bW0GQR1XS
SK-N-AS	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTl6OD6xJI5O	MUPTRW5ITVJ?
ML-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PpeWlEPTB;MT6wNFQxPyEQvF2=	NGrBNHZUSU6JRWK=
MEL-HO	M4KxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPPfZZqUUN3ME2xMlAxPTh{IN88US=>	M1Wy[3NCVkeHUh?=
MS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf6co9KSzVyPUGuNFA3OTdizszN	MW\TRW5ITVJ?
NCI-SNU-1	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HHfmlEPTB;MT6wNlM{OSEQvF2=	M1XRc3NCVkeHUh?=
8505C	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmq0TWM2OD1zLkCyN\|MyKM7:TR?=	MljlV2FPT0WU
MN-60	NYnpN3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLCTWM2OD1zLkCyOlgh\|ryP	M1vLdHNCVkeHUh?=
SAS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFwMESwPFEh\|ryP	MVHTRW5ITVJ?
EFM-19	NYHFNlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUX4[GJYUUN3ME2xMlA1QDd7IN88US=>	M4flWnNCVkeHUh?=
Ca9-22	Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTFwMEWxNFch\|ryP	Mm\EV2FPT0WU
NBsusSR	NEjPRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PrXmlEPTB;MT6wOVE3PiEQvF2=	NHHq[2tUSU6JRWK=
NB13	NF[4UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXnUW1KSzVyPUGuNFU2ODFizszN	M2LmfXNCVkeHUh?=
SF295	NIeyZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\GXZVSUUN3ME2xMlA3PjJ2IN88US=>	NY\mXJAzW0GQR1XS
U-2-OS	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknnTWM2OD1zLkC3PVEyKM7:TR?=	MVzTRW5ITVJ?
NCI-H526	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{j2OWlEPTB;MT6wPFI6OSEQvF2=	M3G3c3NCVkeHUh?=
KMOE-2	NHLWToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fmUmlEPTB;MT6wPVQzOiEQvF2=	M{Lz[HNCVkeHUh?=
RCM-1	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvsTWM2OD1zLkGyNVAzKM7:TR?=	MYHTRW5ITVJ?
MC116	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfmS29KSzVyPUGuNVM3OjFizszN	Mn3yV2FPT0WU
NCI-H1092	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;QTWM2OD1zLkG1OFA3KM7:TR?=	M2j1fXNCVkeHUh?=
EW-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfaTWM2OD1zLkG3NlEzKM7:TR?=	MXzTRW5ITVJ?
HCT-116	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFwMUe3OUDPxE1?	MVnTRW5ITVJ?
MC-IXC	NVTGVJJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXrTWM2OD1zLkG3PFgyKM7:TR?=	M{nzSnNCVkeHUh?=
LB1047-RCC	M4DEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPYTWM2OD1zLkG4N\|EzKM7:TR?=	Mlr4V2FPT0WU
VM-CUB-1	M1;QZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rhcWlEPTB;MT6xPVExQCEQvF2=	MoWxV2FPT0WU
NB5	NFHqToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmq4TWM2OD1zLkG5PFU3KM7:TR?=	NX\qT3V2W0GQR1XS
SKG-IIIa	NHzO[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTFwMkO0OlQh\|ryP	MVrTRW5ITVJ?
HO-1-N-1	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7w[ppKSzVyPUGuNlM5OzVizszN	MoXqV2FPT0WU
EFO-27	M3znXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvaPHdKSzVyPUGuNlUxPDNizszN	NH\ETGlUSU6JRWK=
MHH-NB-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\ZdHA6UUN3ME2xMlI5OzJ7IN88US=>	NETHWJFUSU6JRWK=
SW620	M3rPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrJXXhKSzVyPUGuNlkxOThizszN	M3u0eXNCVkeHUh?=
MOLT-16	MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7oTWM2OD1zLkK5O\|k4KM7:TR?=	NWnwRW9yW0GQR1XS
NTERA-S-cl-D1	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LzPGlEPTB;MT6zNVc3OSEQvF2=	M{TBSHNCVkeHUh?=
VA-ES-BJ	NU\IPYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzPTWM2OD1zLkOyOFc4KM7:TR?=	MYjTRW5ITVJ?
HCC1419	NHPVZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf6c5JWUUN3ME2xMlM1ODJ5IN88US=>	MXjTRW5ITVJ?
NCI-H69	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVSxb2l{UUN3ME2xMlM1OTF{IN88US=>	MX;TRW5ITVJ?
DEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DIR2lEPTB;MT6zOVE3OiEQvF2=	NILsZ29USU6JRWK=
LXF-289	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jmUWlEPTB;MT6zOVI1KM7:TR?=	NGWwZYhUSU6JRWK=
EW-11	NWnsfllET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFwM{[wNlYh\|ryP	MljhV2FPT0WU
KP-4	NWj2fVU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFwM{ewPFUh\|ryP	NGDLTHZUSU6JRWK=
NOS-1	NUnnWmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTFwNEGxPVQh\|ryP	NV7nV3VpW0GQR1XS
SK-NEP-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XyN2lEPTB;MT60NVY6OyEQvF2=	NGGwe3JUSU6JRWK=
LAMA-84	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljRTWM2OD1zLkSzPVQ2KM7:TR?=	Ml;lV2FPT0WU
ES5	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TFcmlEPTB;MT60OFMh\|ryP	NVPjNmluW0GQR1XS
HuO9	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDnTWM2OD1zLkS1N\|YzKM7:TR?=	MX3TRW5ITVJ?
COLO-684	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwNE[xNVgh\|ryP	NY\xcHdkW0GQR1XS
EW-24	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwNE[1N\|Eh\|ryP	MYrTRW5ITVJ?
BV-173	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFSwdohKSzVyPUGuOFczQTFizszN	M1PFNXNCVkeHUh?=
NCI-H1770	Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGG1Z25KSzVyPUGuOFg2OzZizszN	NHHHd\|JUSU6JRWK=
HuP-T4	M1rpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPyTlhKSzVyPUGuOFk{KM7:TR?=	NVKxXlhJW0GQR1XS
TYK-nu	NHyzRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTGTWM2OD1zLkS5PFUyKM7:TR?=	NU\2TIdKW0GQR1XS
YH-13	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDJeWZKSzVyPUGuOFk5QTRizszN	MVXTRW5ITVJ?
H4	NXLxb5ptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTFwNUC5NVIh\|ryP	NFG1U\|BUSU6JRWK=
OVCAR-8	NUTGW25FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHm0RZpKSzVyPUGuOVQ1PzdizszN	MoLrV2FPT0WU
NCI-H23	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;XbYxKSzVyPUGuOVQ3PDVizszN	M1SzfXNCVkeHUh?=
ES7	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fJ[WlEPTB;MT61OFc4OyEQvF2=	MUjTRW5ITVJ?
COR-L88	NIfNdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfRTohJUUN3ME2xMlU3PDJ2IN88US=>	MkXiV2FPT0WU
TI-73	NVWybYxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[3SGlEPTB;MT61PVA3KM7:TR?=	M33nS3NCVkeHUh?=
RT-112	M1PRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PkXWlEPTB;MT61PVI5PCEQvF2=	MnzjV2FPT0WU
HuO-3N1	M1HTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTFwNUmzPFUh\|ryP	MnHuV2FPT0WU
HC-1	M134TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTFwNUm4OlYh\|ryP	MoPEV2FPT0WU
HT55	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTFwNkWxN\|Eh\|ryP	M3uzT3NCVkeHUh?=
IA-LM	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYe5XZViUUN3ME2xMlY6Ojd6IN88US=>	M{PBRnNCVkeHUh?=
EM-2	NG\j[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXGUJJJUUN3ME2xMlcxODF2IN88US=>	MYHTRW5ITVJ?
MHH-ES-1	NGnEZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Tpe2lEPTB;MT63NFQ{PSEQvF2=	NUXh[2VoW0GQR1XS
CAL-27	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULqdnoxUUN3ME2xMlcxPjJzIN88US=>	Mn7GV2FPT0WU
COLO-800	NYP5TFZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGSzXmtKSzVyPUGuO\|EyPzlizszN	M17CWXNCVkeHUh?=
HCE-T	NHW5NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXETWM2OD1zLkexOUDPxE1?	NEDU[VhUSU6JRWK=
CAMA-1	NHXPbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDLUVJKSzVyPUGuO\|E6PzFizszN	M3TUVnNCVkeHUh?=
LOXIMVI	M4Ljc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4L0XGlEPTB;MT63NlEyKM7:TR?=	NUSzPW9LW0GQR1XS
NH-12	M1j1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3niVWlEPTB;MT63NlY6OSEQvF2=	MmX6V2FPT0WU
TCCSUP	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\zTWM2OD1zLkeyPFI6KM7:TR?=	MVXTRW5ITVJ?
MDA-MB-361	NWToOpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\ySVZKSzVyPUGuO\|MyPTdizszN	NXThdYxvW0GQR1XS
EW-16	NILYbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGW5c2pKSzVyPUGuO\|QyODdizszN	MoDEV2FPT0WU
SNU-423	M4j0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVz4TGdDUUN3ME2xMlc2QDJ5IN88US=>	NVjGSWZQW0GQR1XS
Daoy	MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFwN{[zNVkh\|ryP	M4PBdHNCVkeHUh?=
ES4	NYLofGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwN{i3OFEh\|ryP	M1\wXXNCVkeHUh?=
PFSK-1	NHfZZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwOECzO{DPxE1?	MXHTRW5ITVJ?
ES3	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Lz[mlEPTB;MT64NlY5OSEQvF2=	M3PhRXNCVkeHUh?=
ONS-76	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTkTWM2OD1zLkiyPFk4KM7:TR?=	NFL0NY9USU6JRWK=
JVM-3	M4TvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYG5Unh3UUN3ME2xMlg2PDVzIN88US=>	NYjueFhGW0GQR1XS
OS-RC-2	NUG0VZVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrWTWM2OD1zLki3NVUyKM7:TR?=	M3TjUnNCVkeHUh?=
COLO-320-HSR	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTFwOEixPVch\|ryP	MmO3V2FPT0WU
HN	NEeyO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1W3VWlEPTB;MT64PFczPSEQvF2=	MXPTRW5ITVJ?
HT	M{\MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[0fGlEPTB;MT64PFk1PyEQvF2=	MXjTRW5ITVJ?
LoVo	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HwXmlEPTB;MT64PVgyKM7:TR?=	NELnSHZUSU6JRWK=
CGTH-W-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDrTWM2OD1zLki5PVQ3KM7:TR?=	NEjDW\|BUSU6JRWK=
NB6	NGD5[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zhTmlEPTB;MT65NVI6QCEQvF2=	MU\TRW5ITVJ?
EW-22	NFzhZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLFTWM2OD1zLkmyPFg4KM7:TR?=	MUXTRW5ITVJ?
ES6	NGXrOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwOUO2N\|Eh\|ryP	MnjRV2FPT0WU
SCC-15	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\GZWlEPTB;MT65N\|gyQSEQvF2=	M1zuenNCVkeHUh?=
HL-60	NFvmXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTFwOUO5NFIh\|ryP	NF;vfFZUSU6JRWK=
human HOP-92	NGfabpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv4[nl3UUN3ME2xMlk1ODZ3IN88US=>	MkPUV2FPT0WU
SW626	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjhTWM2OD1zLkm0PFk6KM7:TR?=	NFPOeJVUSU6JRWK=
HEC-1	NVfXcZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwOUWzOkDPxE1?	MlLFV2FPT0WU
LB2241-RCC	NVnlS29CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne4TWM2OD1zLkm4NlMyKM7:TR?=	NVe3XmptW0GQR1XS
Ramos-2G6-4C10	NYHpUlZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHJWHpKSzVyPUGuPVk1QTNizszN	NV24OJRjW0GQR1XS
A101D	NUT5WFBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT0TWM2OD1{LkKwN\|A{KM7:TR?=	M1f5S3NCVkeHUh?=
NCI-H446	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n0fWlEPTB;Mj6wOFU6QSEQvF2=	Ml:2V2FPT0WU
SBC-5	M3TsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjlTWM2OD1{LkC2NVQ4KM7:TR?=	NF\ITY1USU6JRWK=
HOS	NUKxU4tDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED5OVlKSzVyPUKuNFc3PTNizszN	NEG3OpNUSU6JRWK=
K5	NE\xRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnJTWM2OD1{LkC3PFEyKM7:TR?=	M1KxOXNCVkeHUh?=
HLE	NHjrZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTJwMEi1Nlkh\|ryP	NIDvO45USU6JRWK=
HSC-2	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzDTGp3UUN3ME2yMlEzQDl6IN88US=>	M3S5bXNCVkeHUh?=
LCLC-97TM1	M4CzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrS[GhqUUN3ME2yMlE1PTh\|IN88US=>	MYHTRW5ITVJ?
DMS-273	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTkVJFiUUN3ME2yMlE1QDN5IN88US=>	MoPwV2FPT0WU
TE-8	M13US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XOOmlEPTB;Mj6xOVc3PSEQvF2=	NUfoZnppW0GQR1XS
DSH1	NXi0S2I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjGZmg1UUN3ME2yMlE3Ozl6IN88US=>	MX3TRW5ITVJ?
CAL-51	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJwMU[2PVkh\|ryP	M{DGeHNCVkeHUh?=
IST-SL1	NYOyOJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\OTWM2OD1{LkG2PFQ1KM7:TR?=	MkH6V2FPT0WU
GCT	NFvSemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnueHhyUUN3ME2yMlE4PzdizszN	M4[wW3NCVkeHUh?=
SW948	M{e0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HnfGlEPTB;Mj6xPFQ2PiEQvF2=	NXm2e5VGW0GQR1XS
NOMO-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3H1TmlEPTB;Mj6xPVMyPyEQvF2=	M2PWVXNCVkeHUh?=
C8166	NYf3foVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHhbZdKSzVyPUKuNlE{OzRizszN	Mk\zV2FPT0WU
OC-314	NXjiOm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVuxfGdkUUN3ME2yMlI{OjV7IN88US=>	M1izcXNCVkeHUh?=
CAL-39	M{O0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LOXmlEPTB;Mj6yN\|YzPiEQvF2=	MWjTRW5ITVJ?
MDA-MB-453	NXjZNoljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljsTWM2OD1{LkK0Nlc2KM7:TR?=	NVPuepZ{W0GQR1XS
A673	NIO1RnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJwMkW4OlIh\|ryP	MnzsV2FPT0WU
HTC-C3	NHzyd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7vTWM2OD1{LkK2PFUh\|ryP	M{D3RnNCVkeHUh?=
NCI-H1666	M2TBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn2zTWM2OD1{LkK4NVEyKM7:TR?=	MW\TRW5ITVJ?
PSN1	M1\5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7xPItKSzVyPUKuNlg6OTNizszN	M3;OU3NCVkeHUh?=
GI-1	M4DIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\5WGlEPTB;Mj6zNFU1OyEQvF2=	NUTHfVduW0GQR1XS
HuH-7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\yTWM2OD1{LkOwOlM4KM7:TR?=	NVvqfppWW0GQR1XS
JAR	M4fofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PWT2lEPTB;Mj6zNVk5PyEQvF2=	MlvLV2FPT0WU
5637	NIjXW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmewTWM2OD1{LkOyNVI6KM7:TR?=	NWrad\|lsW0GQR1XS
GB-1	M2nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLxTWM2OD1{LkOyN\|M2KM7:TR?=	MXvTRW5ITVJ?
KP-N-YS	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjMPWkyUUN3ME2yMlMzPjF3IN88US=>	M4rFWXNCVkeHUh?=
OAW-42	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHNTWM2OD1{LkOzOFE3KM7:TR?=	NYDKR29mW0GQR1XS
8-MG-BA	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfTfHVKSzVyPUKuN\|M6ODZizszN	NIi1ZVFUSU6JRWK=
RH-18	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDOZo1KSzVyPUKuN\|UxOjJizszN	M1K5dHNCVkeHUh?=
NCI-H1155	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH24TpVKSzVyPUKuN\|Y4OjVizszN	NX;4R49oW0GQR1XS
NB17	Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;qOVBKSzVyPUKuN\|gzPDNizszN	MX7TRW5ITVJ?
NCI-H1437	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlP6TWM2OD1{LkSxPFc{KM7:TR?=	NWDOWJV2W0GQR1XS
SN12C	NV7neYNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJwNEOyNVQh\|ryP	NX3YU5F7W0GQR1XS
HSC-3	M1XpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3YTWM2OD1{LkS0OVA6KM7:TR?=	MnvCV2FPT0WU
GAMG	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnS2TWM2OD1{LkS0OVYyKM7:TR?=	MYHTRW5ITVJ?
HT-1080	NWXCSlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz1XI9KSzVyPUKuOFQ5PjRizszN	M1PFPXNCVkeHUh?=
A549	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3SzTGlEPTB;Mj60OFg6OyEQvF2=	M3vtNXNCVkeHUh?=
KNS-62	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJwNEWwOlEh\|ryP	Mm\oV2FPT0WU
YKG-1	M{S1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPyTWM2OD1{LkS1OFM4KM7:TR?=	MWnTRW5ITVJ?
LU-134-A	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfGdmlKSzVyPUKuOFcxODhizszN	NGC1S5NUSU6JRWK=
FADU	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJwNEexOlIh\|ryP	NV3Ob4pnW0GQR1XS
TGBC11TKB	M36wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGizcY1KSzVyPUKuOFcyPzdizszN	M1ryZnNCVkeHUh?=
HT-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFryOpdKSzVyPUKuOFk2OzVizszN	MmriV2FPT0WU
NCI-H2170	NYPIZ2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnkbYhEUUN3ME2yMlUxPTR7IN88US=>	Mnj4V2FPT0WU
Mo-T	M1j2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLsTWM2OD1{LkWwPVI4KM7:TR?=	NUO3R3RsW0GQR1XS
CCRF-CEM	MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{P2[2lEPTB;Mj61N\|A1OyEQvF2=	MVfTRW5ITVJ?
KU-19-19	NVrreGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmntTWM2OD1{LkWzOVE{KM7:TR?=	NEP4e5ZUSU6JRWK=
NCI-H1048	NGfRVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PuN2lEPTB;Mj61OVAzPSEQvF2=	M{PxenNCVkeHUh?=
KOSC-2	NVO3RpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPjdZBKSzVyPUKuOVYxPzZizszN	MXrTRW5ITVJ?
A431	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf6VlZMUUN3ME2yMlU3OzN3IN88US=>	M2L0SnNCVkeHUh?=
COR-L23	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6zTWM2OD1{LkW4OVY3KM7:TR?=	NGHK[2JUSU6JRWK=
MKN28	NVH5VIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJwNUmwN\|ch\|ryP	MoT0V2FPT0WU
22RV1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrXNI1KSzVyPUKuOVkzPzRizszN	MlPrV2FPT0WU
ABC-1	NF:2UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTJwNkC0OkDPxE1?	NFP2VWdUSU6JRWK=
NCI-H2126	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHUWoVKSzVyPUKuOlA6QDRizszN	NI\s[XBUSU6JRWK=
DoTc2-4510	NIT2c3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{G4UWlEPTB;Mj62NlE5PSEQvF2=	NImzUI5USU6JRWK=
SCC-4	NF\3b21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHDUplKSzVyPUKuOlMxOTJizszN	M1i2VXNCVkeHUh?=
NCI-H661	M3nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJwNkSwPFUh\|ryP	MXjTRW5ITVJ?
RPMI-2650	NHqxZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFz5O4lKSzVyPUKuOlQyPDNizszN	MnXaV2FPT0WU
NCI-H510A	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTqd3YzUUN3ME2yMlY1PDJ4IN88US=>	MXzTRW5ITVJ?
BPH-1	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;TTWM2OD1{Lk[1PFUh\|ryP	NH7nWY1USU6JRWK=
M14	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[1WGlEPTB;Mj62Olk6OyEQvF2=	NVTsdY9iW0GQR1XS
G-402	NUPuUHZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTiWmNVUUN3ME2yMlcxPDVzIN88US=>	MmHXV2FPT0WU
AsPC-1	NFn2[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\VTXllUUN3ME2yMlcyOTdizszN	M1;3W3NCVkeHUh?=
NB12	M17ISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFSwXmJKSzVyPUKuO\|E4OSEQvF2=	MlLOV2FPT0WU
SK-HEP-1	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;PSmlEPTB;Mj63OFM6OSEQvF2=	M2KwSnNCVkeHUh?=
U-266	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3QRpdwUUN3ME2yMlc4OTJzIN88US=>	M17Eb3NCVkeHUh?=
AM-38	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXIboVIUUN3ME2yMlc4OzV3IN88US=>	NFPqVFRUSU6JRWK=
PC-14	NXz4N4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJwOEC1NUDPxE1?	MYfTRW5ITVJ?
EGI-1	M{PuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LqO2lEPTB;Mj64NVc1OyEQvF2=	M2ixdXNCVkeHUh?=
LS-411N	NIO2WmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJwOEKzN{DPxE1?	NYXJPIo5W0GQR1XS
BFTC-905	NX\sOWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXjVHlKSzVyPUKuPFU2OjNizszN	NWG5dlVCW0GQR1XS
CaR-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJwOE[g{txO	NY\p[YxpW0GQR1XS
NCI-H292	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHTPGdiUUN3ME2yMlg3PTl4IN88US=>	MVzTRW5ITVJ?
8305C	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XsdmlEPTB;Mj64OlY1PSEQvF2=	M2rtW3NCVkeHUh?=
SNU-449	NGr2NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF63fmRKSzVyPUKuPFkyQDJizszN	NUGzcmpNW0GQR1XS
LCLC-103H	NFTp[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzTdolKSzVyPUKuPVA1OzhizszN	M2PveHNCVkeHUh?=
SW1573	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTJwOU[wPFIh\|ryP	NHfQXpNUSU6JRWK=
MLMA	NF35c3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LIPGlEPTB;Mj65OlcyPyEQvF2=	NEHaWWVUSU6JRWK=
NCI-H1355	NGm5eHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXKzUYxPUUN3ME2zMlAxPzl4IN88US=>	MX\TRW5ITVJ?
RMG-I	M4i5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfIbpV6UUN3ME2zMlAzPTl{IN88US=>	M2LO[nNCVkeHUh?=
BB65-RCC	NI\LTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmKwTWM2OD1\|LkCzN\|E1KM7:TR?=	NIqxUVZUSU6JRWK=
PC-3	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3qZ\|JKSzVyPUOuNFM5PzRizszN	MofVV2FPT0WU
SF268	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUC1dpVvUUN3ME2zMlA1PTJ\|IN88US=>	MXLTRW5ITVJ?
NCI-H810	NH;EbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TwN2lEPTB;Mz6wOFgzOyEQvF2=	NVjwPVBxW0GQR1XS
MEG-01	M2Gw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTNwME[xOlQh\|ryP	MX;TRW5ITVJ?
SW13	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PnRWlEPTB;Mz6wO\|g1PyEQvF2=	NIT6WllUSU6JRWK=
RH-1	NF;nRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\aTWM2OD1\|LkGwNlc5KM7:TR?=	MWLTRW5ITVJ?
GT3TKB	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4G0Z2lEPTB;Mz6xNVI5OyEQvF2=	MnfMV2FPT0WU
TK10	Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVr4eW9WUUN3ME2zMlE{PzJ2IN88US=>	MXXTRW5ITVJ?
T-24	M{jzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFL4XI9KSzVyPUOuNVUxPyEQvF2=	NFftO3FUSU6JRWK=
A498	M4rsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWW1TVVSUUN3ME2zMlIxQDdzIN88US=>	NXjURZlFW0GQR1XS
GR-ST	NX3NOmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTNwMkKxN\|kh\|ryP	NYLp[nBEW0GQR1XS
LB2518-MEL	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XyUWlEPTB;Mz6yNlM6QCEQvF2=	NIT6XY1USU6JRWK=
T47D	NV[3N5pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLWTWM2OD1\|LkKzOlI4KM7:TR?=	MXTTRW5ITVJ?
NCI-H1651	NHvzOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkH3TWM2OD1\|LkK0OlQ1KM7:TR?=	NGDGOldUSU6JRWK=
EC-GI-10	NWXGO4pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml:4TWM2OD1\|LkK2NVU{KM7:TR?=	M2KwbHNCVkeHUh?=
HT-29	M3PQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHPVId3UUN3ME2zMlI3PjF2IN88US=>	MlfiV2FPT0WU
GI-ME-N	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfnZXhIUUN3ME2zMlI6PTFzIN88US=>	MUPTRW5ITVJ?
SW756	NXLUUndbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTNwMkm2Nlkh\|ryP	MXTTRW5ITVJ?
RKO	NIrZPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTtdXh4UUN3ME2zMlMxPzV5IN88US=>	NHztWppUSU6JRWK=
NCI-H1563	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVviTVEzUUN3ME2zMlM{ODF6IN88US=>	Mon2V2FPT0WU
DJM-1	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fVPWlEPTB;Mz6zO\|Y4PCEQvF2=	MVLTRW5ITVJ?
L-428	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4L6R2lEPTB;Mz60NFA1PSEQvF2=	NF\qXVZUSU6JRWK=
NCI-H2122	NH[yWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEThdYxKSzVyPUOuOFE{OTJizszN	NVKx[\|V2W0GQR1XS
Ca-Ski	NH;1NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHnS\|JKSzVyPUOuOFU1OyEQvF2=	NYi3VZd4W0GQR1XS
639-V	NIHFRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTNwNE[wOVch\|ryP	MonhV2FPT0WU
SW1116	NEXLU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTNwNE[yOlkh\|ryP	M{\kWHNCVkeHUh?=
DMS-114	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEK5VVdKSzVyPUOuOFcxPjZizszN	MUHTRW5ITVJ?
MZ2-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPETWM2OD1\|LkS3OlgyKM7:TR?=	M4jjWHNCVkeHUh?=
COLO-829	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2H5fmlEPTB;Mz61NFA4OyEQvF2=	M4X0UnNCVkeHUh?=
J82	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{D4cGlEPTB;Mz61NFU4KM7:TR?=	MlPYV2FPT0WU
EW-13	NEG5eW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu5SZhKSzVyPUOuOVI2OSEQvF2=	MYrTRW5ITVJ?
RXF393	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mke5TWM2OD1\|LkWzNlk1KM7:TR?=	NHjBcW5USU6JRWK=
CAL-62	NYHnS3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HKN2lEPTB;Mz61OFUyPCEQvF2=	NFfySWRUSU6JRWK=
OCUB-M	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHZWoZKSzVyPUOuOVQ3PjVizszN	M{LkVHNCVkeHUh?=
BT-474	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jtemlEPTB;Mz62N\|MyKM7:TR?=	NW\0b4tKW0GQR1XS
KYSE-180	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nQdmlEPTB;Mz62N\|M4OiEQvF2=	MYXTRW5ITVJ?
NCI-H650	NGnsTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPWXJNYUUN3ME2zMlY1Ojh5IN88US=>	MmHKV2FPT0WU
Detroit562	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnJTIdKSzVyPUOuOlUxOjJizszN	NGfDZ3FUSU6JRWK=
SW48	NW\BbI82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTNwNkW2OVch\|ryP	NGTEO3hUSU6JRWK=
KYSE-450	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[wfZloUUN3ME2zMlY5PTh{IN88US=>	NVPIb25TW0GQR1XS
KYSE-510	NYjhZZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3qXnlKSzVyPUOuO\|IyQDFizszN	NFzae5VUSU6JRWK=
GP5d	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fWOmlEPTB;Mz63Nlk2KM7:TR?=	MYLTRW5ITVJ?
RPMI-7951	NV7TSWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXaO4hKSzVyPUOuO\|Q4OjNizszN	MoXlV2FPT0WU
Becker	NWLPR5lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTITWM2OD1\|Lke1NFEzKM7:TR?=	NWjVTW9FW0GQR1XS
WM-115	NHLueItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\PcYk5UUN3ME2zMlc5OTl3IN88US=>	MX3TRW5ITVJ?
G-401	NEnH[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnyVIttUUN3ME2zMlc6ODh3IN88US=>	M1npTnNCVkeHUh?=
PANC-08-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTNwN{m2NFIh\|ryP	NYXlRlkzW0GQR1XS
SW982	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PrSWlEPTB;Mz64NFU2OSEQvF2=	NFvJVlNUSU6JRWK=
D-263MG	MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfuN3BnUUN3ME2zMlgzODVzIN88US=>	NGjJRlVUSU6JRWK=
KM-H2	NUHLUolkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTNwOEK2NlQh\|ryP	NH7WcYhUSU6JRWK=
SK-MEL-3	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUH2fWkyUUN3ME2zMlgzQDRzIN88US=>	NX\tN5REW0GQR1XS
NCI-H1581	M1PPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLvTWM2OD1\|Lki0OFg5KM7:TR?=	MlP4V2FPT0WU
LS-123	M4XIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn4SJRNUUN3ME2zMlg4QTB7IN88US=>	MlPyV2FPT0WU
CAKI-1	M2m3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nPU2lEPTB;Mz64PVA2OiEQvF2=	NH31ZVBUSU6JRWK=
MEL-JUSO	NVfUUY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXUeVN1UUN3ME2zMlg6OTV\|IN88US=>	NELjOm1USU6JRWK=
HCE-4	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LqbGlEPTB;Mz65NVY3OyEQvF2=	M33yT3NCVkeHUh?=
TE-10	M3LRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTNwOUKwNUDPxE1?	NX7G[4c5W0GQR1XS
OVCAR-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTNwOUK4PFkh\|ryP	NVTye2s6W0GQR1XS
ETK-1	M17MVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnaZ4hqUUN3ME2zMlk1PjN3IN88US=>	M1jnZ3NCVkeHUh?=
A2780	NEXBeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTRwMEW5OlYh\|ryP	NIjnTZpUSU6JRWK=
LU-65	M{fRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWeze2pTUUN3ME20MlA4PjN\|IN88US=>	NYiyfmh1W0GQR1XS
BHY	NGrSepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nhXGlEPTB;ND6xNlQ6PSEQvF2=	Mo\5V2FPT0WU
COR-L105	NWjJSXlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHvTWM2OD12LkGzNFUyKM7:TR?=	M{mxcHNCVkeHUh?=
CAL-12T	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknLTWM2OD12LkGzNVA{KM7:TR?=	M2ToV3NCVkeHUh?=
SCH	MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XnV2lEPTB;ND6xOVc1OyEQvF2=	NWfpeZNOW0GQR1XS
CW-2	M1LQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTRwMUmwNFEh\|ryP	MVrTRW5ITVJ?
HCC1806	M1vHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTRwMkCzNVIh\|ryP	M3yyc3NCVkeHUh?=
KP-N-YN	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XJbmlEPTB;ND6yNFkzPyEQvF2=	NIXKNlBUSU6JRWK=
T98G	NUO5Snc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnFcI9KSzVyPUSuNlIyPTdizszN	NHXwOJJUSU6JRWK=
CAL-54	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HJS2lEPTB;ND6yNlM5OSEQvF2=	NUfjR4RIW0GQR1XS
CAL-33	NWX4RlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFztbnVKSzVyPUSuNlMxPjRizszN	NHzIW5BUSU6JRWK=
SNU-C2B	M2jWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3izb2lEPTB;ND6yOFc3QSEQvF2=	M{TUenNCVkeHUh?=
NUGC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfm[JBKSzVyPUSuNlU2ODVizszN	Ml;yV2FPT0WU
DOK	M1vY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPPTWM2OD12LkK2OVk{KM7:TR?=	NH3LcXZUSU6JRWK=
MMAC-SF	NIX0WHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnQTWM2OD12LkK2PFU6KM7:TR?=	M3\WSHNCVkeHUh?=
KYSE-70	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TYTWlEPTB;ND6yPVM1KM7:TR?=	NIO1eHFUSU6JRWK=
A204	M4TXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTRwM{W4NFMh\|ryP	M13rZnNCVkeHUh?=
SCC-25	M3vwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTRwM{W4NVkh\|ryP	MorWV2FPT0WU
EPLC-272H	NUnsXpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknTTWM2OD12LkO4PVUh\|ryP	MY\TRW5ITVJ?
CAL-120	NVjsPZB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPNfVZ6UUN3ME20MlM5QTl{IN88US=>	M1rtNnNCVkeHUh?=
LS-513	NXH2NWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLEZmw4UUN3ME20MlQzOTl6IN88US=>	MYfTRW5ITVJ?
CAPAN-1	NUjNXGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fKbGlEPTB;ND60NlM5OiEQvF2=	NYHzPJhFW0GQR1XS
ESS-1	NIDJZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTRwNEK3NlQh\|ryP	M4C3THNCVkeHUh?=
GMS-10	NVL4XFluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTRwNEK4NVkh\|ryP	NFjQdnlUSU6JRWK=
NCI-N87	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTLSZZKSzVyPUSuOVA5PjhizszN	M4TIZnNCVkeHUh?=
HMV-II	M2HHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HUWWlEPTB;ND61NVc{KM7:TR?=	NWr2SXNHW0GQR1XS
COLO-741	MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTRwNUW5PVQh\|ryP	NHzaSWhUSU6JRWK=
MKN45	NULFVVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInYNZNKSzVyPUSuOVc4OzJizszN	NXrEW49rW0GQR1XS
OAW-28	M1vRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTuOZFKSzVyPUSuOVg{QThizszN	NWfB[ZU6W0GQR1XS
OCI-AML2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGe0U4VKSzVyPUSuOlUzOzhizszN	NXHBdJpvW0GQR1XS
MDA-MB-231	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\sTWM2OD12LkewNlQ{KM7:TR?=	NETqVIxUSU6JRWK=
NCI-H1648	NWTY[4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\ETWM2OD12LkeyNlc{KM7:TR?=	NFjjW4dUSU6JRWK=
NCI-H1792	NYjS[5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnyWWpKSzVyPUSuO\|YyODdizszN	MlPsV2FPT0WU
GCIY	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDzO5l{UUN3ME20Mlc4PDJ2IN88US=>	MYrTRW5ITVJ?
Hs-578-T	NGSxSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4exUWlEPTB;ND63O\|Y2PSEQvF2=	NFnVVYVUSU6JRWK=
SW962	NFzWR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3e2PGlEPTB;ND63PFAyOSEQvF2=	Moi2V2FPT0WU
NCI-H630	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULLfGpsUUN3ME20Mlc5ODhzIN88US=>	NVXjTZpTW0GQR1XS
786-0	MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknlTWM2OD12Lke4O\|c{KM7:TR?=	M4nqenNCVkeHUh?=
FTC-133	NWnGT3huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vqR2lEPTB;ND63PVI3OyEQvF2=	MUTTRW5ITVJ?
BT-20	NH\6UpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3v3Z2lEPTB;ND63PVQzQSEQvF2=	NHztVYZUSU6JRWK=
Mewo	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTRwOEG3OFch\|ryP	NH3adY5USU6JRWK=
SW780	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTRwOEW3OlYh\|ryP	MoHuV2FPT0WU
OE33	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL2e\|BpUUN3ME20Mlg4PzF\|IN88US=>	MWDTRW5ITVJ?
HCC1569	NHzXSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TuNmlEPTB;ND64PFQ2QCEQvF2=	NUjxXW1yW0GQR1XS
TE-6	M2HHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTRwOUO5O\|ch\|ryP	NE[0eINUSU6JRWK=
SK-N-FI	NEjPeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjOfldKSzVyPUSuPVQ1OjFizszN	M1TRS3NCVkeHUh?=
PANC-03-27	NGfVNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTRwOUm5OlIh\|ryP	M4n5d3NCVkeHUh?=
MCF7	M3TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTVwMEC3N\|gh\|ryP	NEnofYZUSU6JRWK=
UACC-257	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTVwMEK4OFUh\|ryP	NEDxSoZUSU6JRWK=
SW1088	NVX6bYNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTVwMEK5OFQh\|ryP	NHrsTZFUSU6JRWK=
A704	M4fCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn:1TWM2OD13LkCzNFYh\|ryP	MVHTRW5ITVJ?
A2058	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTVwMEW5NFgh\|ryP	NH;3V2dUSU6JRWK=
Calu-3	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTVwME[0OVIh\|ryP	MlrPV2FPT0WU
RERF-LC-MS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;DdXBKSzVyPUWuNFY6ODNizszN	Mn73V2FPT0WU
AU565	NHfFVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLxcVFRUUN3ME21MlA6PzB{IN88US=>	NWn4foU4W0GQR1XS
DMS-79	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTVwMUO4PFMh\|ryP	MnvUV2FPT0WU
DK-MG	NGXjOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnmPI9KSzVyPUWuNVg1OzhizszN	NHPZ[mFUSU6JRWK=
HuCCT1	NUH4Z\|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:5WG0xUUN3ME21MlI{QDV4IN88US=>	NHzESYFUSU6JRWK=
HT-144	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTVwMkS5PFch\|ryP	MVfTRW5ITVJ?
M059J	NH3VfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXW0epNMUUN3ME21MlI2PzZizszN	NIGyZlBUSU6JRWK=
COLO-792	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjNTWM2OD13LkK2N\|U3KM7:TR?=	NHixS4pUSU6JRWK=
SF539	NFHqclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P4c2lEPTB;NT6yOlY{OiEQvF2=	MljSV2FPT0WU
SK-UT-1	M4Ln[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnL3TWM2OD13LkK3O\|UyKM7:TR?=	MVjTRW5ITVJ?
NCI-H1703	NVvBbmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\DTWM2OD13LkO1PFI3KM7:TR?=	NY\vU49FW0GQR1XS
SW837	M2faXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXvZXFlUUN3ME21MlM4QDd6IN88US=>	NEDhSlZUSU6JRWK=
U251	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\INoVLUUN3ME21MlM6ODl4IN88US=>	NIP1cWtUSU6JRWK=
SW1710	M3vBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DqPWlEPTB;NT60NVU2PCEQvF2=	MlKzV2FPT0WU
NCI-H1299	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDibYE{UUN3ME21MlQ3OzN3IN88US=>	M{\BeHNCVkeHUh?=
RVH-421	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXKeYxwUUN3ME21MlQ6QTB6IN88US=>	MWTTRW5ITVJ?
UM-UC-3	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTVwNkK2OVEh\|ryP	M{L5WHNCVkeHUh?=
MDA-MB-175-VII	M2nCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTVwNkSwOFEh\|ryP	NWrXRodvW0GQR1XS
KYSE-270	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\jUXVEUUN3ME21MlY3ODNzIN88US=>	MofXV2FPT0WU
COLO-668	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7YOpJmUUN3ME21MlcyOzJizszN	M{DzT3NCVkeHUh?=
LN-405	NUD2SVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTVwN{OwPFUh\|ryP	NVvyO\|dLW0GQR1XS
HT-1376	NV;pUlFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfkflJvUUN3ME21Mlc5ODV{IN88US=>	MnK2V2FPT0WU
769-P	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTVwOE[3NVgh\|ryP	NEHrN5NUSU6JRWK=
HuP-T3	NX\aeVBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTVwOEi2O\|ch\|ryP	MV\TRW5ITVJ?
MDA-MB-415	NVjxU2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XZPWlEPTB;NT65NlE{QSEQvF2=	MXTTRW5ITVJ?
MKN7	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHxfGhKSzVyPUWuPVg5KM7:TR?=	NIPSVnlUSU6JRWK=
KS-1	M13L[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTVwOUi4N\|Yh\|ryP	M3zPT3NCVkeHUh?=
647-V	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXUOWlVUUN3ME21Mlk6OTR6IN88US=>	M1vrR3NCVkeHUh?=
COLO-679	NF3qOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrETWM2OD14LkCwNlU2KM7:TR?=	MWLTRW5ITVJ?
AN3-CA	NIDnfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTZwMEO0OFEh\|ryP	MornV2FPT0WU
C32	NGmw[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33tdWlEPTB;Nj6xN\|A{PCEQvF2=	NEPJXpFUSU6JRWK=
KM12	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTZwMkSwPVkh\|ryP	NVvGNFd6W0GQR1XS
KINGS-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\ZO2lEPTB;Nj6yOlE2OiEQvF2=	MYHTRW5ITVJ?
KYSE-410	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfnTWM2OD14LkOwOlQ2KM7:TR?=	MlP5V2FPT0WU
HPAF-II	NIf2d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1mxbmlEPTB;Nj6zOVQ5KM7:TR?=	NWnabpltW0GQR1XS
LAN-6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTZwNEm2N\|Eh\|ryP	NF;nXGdUSU6JRWK=
LU-99A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXXN45DUUN3ME22MlU2QTh7IN88US=>	MlX5V2FPT0WU
SJSA-1	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLNR\|liUUN3ME22MlU3OzR5IN88US=>	NFT2eYtUSU6JRWK=
MSTO-211H	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHPTWM2OD14LkeyNlM{KM7:TR?=	NYDJUZQ{W0GQR1XS
SW900	M{HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTZwN{[yNlEh\|ryP	M1HlSHNCVkeHUh?=
LNCaP-Clone-FGC	M2DCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXztT2JtUUN3ME22MlgxPDB\|IN88US=>	M32w[nNCVkeHUh?=
OMC-1	NH;WUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljrTWM2OD14Lki1OFAzKM7:TR?=	MV7TRW5ITVJ?
IST-MEL1	Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7De4dJUUN3ME22Mlg6PjZ7IN88US=>	MUTTRW5ITVJ?
TE-9	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTZwOEm4OFch\|ryP	NFOxenNUSU6JRWK=
NCI-H2030	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jvTmlEPTB;Nj65NVIzPiEQvF2=	NHHCSWZUSU6JRWK=
BFTC-909	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTdwMEC2OFEh\|ryP	MUjTRW5ITVJ?
NCI-SNU-5	NVLyWFBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfjOYZKSzVyPUeuNFIyPTlizszN	NGnkUXJUSU6JRWK=
TE-5	NEHYboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rOWGlEPTB;Nz6wNlg5OSEQvF2=	NXLEeJRGW0GQR1XS
SK-MES-1	M1:2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvKSnVKSzVyPUeuNFU1OjdizszN	NGPEZ2RUSU6JRWK=
SHP-77	NWjPO5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHWxNHRKSzVyPUeuNVM6PTJizszN	M1\xZXNCVkeHUh?=
NCI-H1623	NHvzN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jFUGlEPTB;Nz6xOFA4OiEQvF2=	MW\TRW5ITVJ?
TE-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTdwMUWxPFQh\|ryP	NGX0bohUSU6JRWK=
EKVX	M3XqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MomyTWM2OD15LkG5NlY4KM7:TR?=	M{LtfHNCVkeHUh?=
OVCAR-3	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi1T3dKSzVyPUeuNlEyOzNizszN	NW\Jc\|JTW0GQR1XS
C3A	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\OcnpsUUN3ME23MlM1PTJizszN	M2DWcXNCVkeHUh?=
CFPAC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDJTWM2OD15LkO2NlIzKM7:TR?=	M1j3TnNCVkeHUh?=
MG-63	M3HUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTZNoZKSzVyPUeuOFE5PDlizszN	NVLLe21uW0GQR1XS
KYSE-140	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGCwSXVKSzVyPUeuOFQxPjFizszN	MnXRV2FPT0WU
MPP-89	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHvTWM2OD15LkW5O\|I6KM7:TR?=	MVLTRW5ITVJ?
COLO-824	NYPjZlFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnnZo9KSzVyPUeuO\|I5PjNizszN	M4XTW3NCVkeHUh?=
SiHa	NEi3O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTdwOEO3NFch\|ryP	NYT1Vo9iW0GQR1XS
SNU-387	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIKwWGNKSzVyPUeuPFU{PDdizszN	NEjldVFUSU6JRWK=
A172	NW\sfHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoWzTWM2OD15Lki2NVczKM7:TR?=	M4PwZXNCVkeHUh?=
COLO-680N	NXrlN\|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTdwOUG3N{DPxE1?	MWnTRW5ITVJ?
HCC1395	NUTwRmJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3aTWM2OD16LkC1OFUzKM7:TR?=	NFrlPG1USU6JRWK=
NCI-H28	M2rFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1npSGlEPTB;OD6wOVk3OyEQvF2=	MofVV2FPT0WU
LC-2-ad	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHsN2pWUUN3ME24MlIyQTN5IN88US=>	MUnTRW5ITVJ?
S-117	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TtNGlEPTB;OD6yOVM2OyEQvF2=	NWrJXWp1W0GQR1XS
NCI-H1838	NGrt[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[3cmlEPTB;OD6yOVc5OSEQvF2=	NHnPVm9USU6JRWK=
PANC-10-05	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHycWJKSzVyPUiuN\|cxPDdizszN	M4nYZ3NCVkeHUh?=
KALS-1	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\5VJRGUUN3ME24MlUxQTJ6IN88US=>	MnvsV2FPT0WU
LS-1034	NYG1b2N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGL1fWdKSzVyPUiuOVc1OzdizszN	NGjEeVlUSU6JRWK=
TGBC1TKB	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRThwN{O1N\|Uh\|ryP	MkHnV2FPT0WU
OE19	NEHZSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDvTGRKSzVyPUiuO\|YzPjJizszN	MYrTRW5ITVJ?
D-502MG	NXvQVFJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRThwN{[5PVQh\|ryP	NXf1ZmF7W0GQR1XS
JEG-3	NYD4ZlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRThwN{i2NVgh\|ryP	MYTTRW5ITVJ?
DBTRG-05MG	NVj4cY01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DvS2lEPTB;OD64O\|U3PSEQvF2=	NHe0[nhUSU6JRWK=
ME-180	NXz5emRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTlwME[3NlUh\|ryP	MYrTRW5ITVJ?
NCI-H1573	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTselZKSzVyPUmuNVA2OzJizszN	M4DMSnNCVkeHUh?=
HCC2998	NX7Sb3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1[5e2lEPTB;OT6xN\|Y5OSEQvF2=	MmHOV2FPT0WU
ACHN	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjsOm1KSzVyPUmuNlQ6PzVizszN	MknwV2FPT0WU
D-392MG	NIrMblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jTRWlEPTB;OT6yOVcyPSEQvF2=	NWjzZ5R{W0GQR1XS
no-11	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTlwMk[wNlgh\|ryP	MYXTRW5ITVJ?
KLE	NHL0folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTlwM{KyN\|Ih\|ryP	M4G4dHNCVkeHUh?=
Calu-6	NFjKfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\rTWM2OD17LkO3OVI5KM7:TR?=	NYLremxRW0GQR1XS
LB831-BLC	M36xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7Zc4NKSzVyPUmuOFUyPzFizszN	MYnTRW5ITVJ?
SW684	M3nheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DYWWlEPTB;OT60OlEyPiEQvF2=	M4nBUXNCVkeHUh?=
SH-4	NF\mRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTlwNEmzOlQh\|ryP	NEnIT2tUSU6JRWK=
IST-MES1	M3TZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfGW2VKSzVyPUmuOVE3PDRizszN	NV;lO\|RqW0GQR1XS
Saos-2	M3vmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIK3OVFKSzVyPUmuOVIyQTVizszN	M4GwUXNCVkeHUh?=
NCI-H2087	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MliwTWM2OD17Lk[3N\|UzKM7:TR?=	NGfVPXFUSU6JRWK=
SCC-9	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\lUZJKSzVyPUmuO\|E5OTZizszN	NY[wO5FtW0GQR1XS
MFE-280	NUHHS\|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnqdYFlUUN3ME25MlczPzh3IN88US=>	M{W2cXNCVkeHUh?=
BEN	M1jEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDj[XNGUUN3ME25MlgzOTV7IN88US=>	MmPTV2FPT0WU
CP50-MEL-B	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXK1dHB[UUN3ME25MlkzPDN{IN88US=>	NH;afG9USU6JRWK=
SK-MEL-28	NHzC[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFyLkCxPVMh\|ryP	NVr5RVV{W0GQR1XS
NCI-H2452	NILJOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDq[4NKSzVyPUGwMlE3KM7:TR?=	NV;SSFlUW0GQR1XS
NCI-H1395	NVLoPGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPYO49KSzVyPUGwMlE4QCEQvF2=	MknwV2FPT0WU
NCI-H2052	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;PW2lEPTB;MUCuNVg5OiEQvF2=	NYDEV29VW0GQR1XS
A375	M4fXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDTTWM2OD1zMD6yOFUzKM7:TR?=	NET2bolUSU6JRWK=
HCC38	NYfEWXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvW[XNnUUN3ME2xNE4{OjJizszN	MV;TRW5ITVJ?
LK-2	M{H3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7sdpBKSzVyPUGwMlQzODhizszN	NEjlWm5USU6JRWK=
SF126	NXv4ZW1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrNTYlmUUN3ME2xNE41PzJ5IN88US=>	MUXTRW5ITVJ?
SK-MEL-1	NXPwOJRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTrN4k1UUN3ME2xNE44QDN6IN88US=>	NILwZppUSU6JRWK=
ACN	NF3seXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PFVmlEPTB;MUCuPFY4QSEQvF2=	NHrpXJNUSU6JRWK=
BB30-HNC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfmOldKSzVyPUGwMlg4OTFizszN	MXLTRW5ITVJ?
NCI-H747	NE\pbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LNTmlEPTB;MUCuPFc1PiEQvF2=	MVHTRW5ITVJ?
KYSE-150	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTFzLkCzPFch\|ryP	MXTTRW5ITVJ?
D-247MG	NH7Pd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPPe\|FKSzVyPUGxMlExODlizszN	NEDyc4lUSU6JRWK=
BxPC-3	NEPZbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfGWlVHUUN3ME2xNU4{PzR5IN88US=>	NEnpUHpUSU6JRWK=
SK-MEL-30	M1vROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf2ZlBKSzVyPUGxMlQxPzlizszN	NXWyPYxxW0GQR1XS
CAS-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPoN4NKSzVyPUGxMlQyODlizszN	NYLhdWl{W0GQR1XS
no-10	MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr6TWM2OD1zMj6xNlE4KM7:TR?=	M3XJcHNCVkeHUh?=
NCI-H2405	M{TM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2P4TWlEPTB;MUKuNlA{PiEQvF2=	MWTTRW5ITVJ?
KGN	NIDseHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnBNVU5UUN3ME2xNk4zQTBzIN88US=>	NGm2emRUSU6JRWK=
BB49-HNC	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mle5TWM2OD1zMj6zPVU3KM7:TR?=	MorLV2FPT0WU
NCI-H1693	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoS3TWM2OD1zMj61PFE3KM7:TR?=	NEf1bWJUSU6JRWK=
RO82-W-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF\|LkC2OFkh\|ryP	MnrtV2FPT0WU
CAL-85-1	M1PTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn3TWM2OD1zMz60N\|k6KM7:TR?=	MV7TRW5ITVJ?
H-EMC-SS	M{TPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTaTWM2OD1zMz65NVA1KM7:TR?=	M17yNnNCVkeHUh?=
SW1783	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTF2LkKzPVEh\|ryP	NVWyNGZxW0GQR1XS
LB771-HNC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TNVGlEPTB;MUSuOFE6KM7:TR?=	NV3MZ3ZmW0GQR1XS
HCC70	M3vBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmqwTWM2OD1zND60NlM{KM7:TR?=	MUjTRW5ITVJ?
KNS-81-FD	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nqVmlEPTB;MUSuO\|A1PSEQvF2=	M2DWTnNCVkeHUh?=
KYSE-520	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEWwW5VKSzVyPUG0MlkzPyEQvF2=	NH\Vc2lUSU6JRWK=
TGBC24TKB	MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnMfXc3UUN3ME2xOE46PTN7IN88US=>	NXH4Nlg4W0GQR1XS
SNB75	NFSzempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF3LkC3Nlkh\|ryP	M{j4VHNCVkeHUh?=
SW872	NXm1XXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTF3LkKyNVgh\|ryP	NXPIcG9KW0GQR1XS
U031	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3CTWM2OD1zNT64NFI5KM7:TR?=	NVXiVZBPW0GQR1XS
ChaGo-K-1	M4DTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PsV2lEPTB;MUWuPFM2QSEQvF2=	MoW4V2FPT0WU
NCI-H441	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTF4LkCwN\|kh\|ryP	NXLZSG5qW0GQR1XS
TE-12	MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M32yVGlEPTB;MU[uNVg4OyEQvF2=	M{jYUXNCVkeHUh?=
NCI-H1755	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\OVlBKSzVyPUG2MlU4OyEQvF2=	M3v6[HNCVkeHUh?=
KNS-42	M4PFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF4Lk[1PFkh\|ryP	M4XkPHNCVkeHUh?=
SK-PN-DW	Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jnZmlEPTB;MUeuOFIxOSEQvF2=	MkfQV2FPT0WU
NCI-H226	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LjZmlEPTB;MUeuPVM1PSEQvF2=	M1\3dHNCVkeHUh?=
K-562	M{j6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIL5SpVKSzVyPUG4MlY{OTdizszN	MXHTRW5ITVJ?
A388	NVfk[Xk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTF7LkCzNFMh\|ryP	MWfTRW5ITVJ?
ZR-75-30	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zVXmlEPTB;MUmuNFk3QCEQvF2=	MYHTRW5ITVJ?
LU-135	M1XkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXBTYNKSzVyPUG5MlI3OzZizszN	NETi[pRUSU6JRWK=
NCI-H2029	M3jkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF7Lk[wNlEh\|ryP	M{jmPHNCVkeHUh?=
HT-1197	NVXP[HlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLKTWM2OD1zOT65NlI4KM7:TR?=	M170TnNCVkeHUh?=
IGR-1	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTJyLkOxNVch\|ryP	M3HVT3NCVkeHUh?=
U-87-MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJyLk[0NVMh\|ryP	MXLTRW5ITVJ?
NCI-H1304	NYDCcnVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVj2N4ZlUUN3ME2yNE44PTBzIN88US=>	MlrtV2FPT0WU
RCC10RGB	MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mni2TWM2OD1{MT6yPFI6KM7:TR?=	MlvqV2FPT0WU
NCI-H520	NEjERZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvlV4tlUUN3ME2yNk44PjFzIN88US=>	M3\6WnNCVkeHUh?=
SK-LU-1	NGLKXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PJNGlEPTB;MkOuNFcyQCEQvF2=	NEjkN3lUSU6JRWK=
UACC-893	NXXp[2pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\ZRWlEPTB;MkOuNVA{QCEQvF2=	M3XTPHNCVkeHUh?=
NCI-H2347	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTJ\|LkK2O\|Qh\|ryP	NXjCfoFRW0GQR1XS
U-118-MG	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\NTWM2OD1{Mz63NlE4KM7:TR?=	M1nyNnNCVkeHUh?=
NCI-H596	NXzVb2RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnDTWM2OD1{Mz65NFU2KM7:TR?=	MYTTRW5ITVJ?
MZ1-PC	M4LsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHhcGYyUUN3ME2yOE43PzV7IN88US=>	NV3IPI5uW0GQR1XS
SW1417	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\Tbo1bUUN3ME2yOU4zPDl6IN88US=>	MXzTRW5ITVJ?
NCI-H82	NHnnTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDITWM2OD1{Nj60Nlg5KM7:TR?=	M{jYeXNCVkeHUh?=
COLO-678	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXzTWM2OD1{Nz60PVE6KM7:TR?=	Mnr2V2FPT0WU
KURAMOCHI	M3uxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jzOWlEPTB;MkiuNVI3KM7:TR?=	MnvpV2FPT0WU
NCI-H1650	NIfRVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWm4OGRJUUN3ME2zNE4yQTJ2IN88US=>	NH\mTZVUSU6JRWK=
HCC1954	NI\E[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\0TWM2OD1\|MT6zOlY3KM7:TR?=	MYPTRW5ITVJ?
GAK	M1TKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17WNGlEPTB;M{KuNlYyPiEQvF2=	NXrsV4VpW0GQR1XS
YAPC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLVR4ZGUUN3ME2zN{44PjR6IN88US=>	NIWweVJUSU6JRWK=
NCI-H2228	M1u3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PPbWlEPTB;M{SuN\|YxPSEQvF2=	M3HDZ3NCVkeHUh?=
VMRC-RCZ	M1izTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPpenJKSzVyPUO2MlMxOjJizszN	MXPTRW5ITVJ?
NMC-G1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X5eGlEPTB;M{euNFUzQSEQvF2=	MnLyV2FPT0WU
D-336MG	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXZTWM2OD12MT64OFQzKM7:TR?=	NFS4RYdUSU6JRWK=
UACC-62	NV[wT\|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUj1V2FTUUN3ME20Nk42PTB3IN88US=>	MkmxV2FPT0WU
C-33-A	NVS4cJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX6yfVNWUUN3ME20OU4{OjV4IN88US=>	NYK4bWxSW0GQR1XS
HCC1937	M4PXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTR5LkG5OVgh\|ryP	NGjiNG5USU6JRWK=
HDLM-2	NH\rNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDvTWM2OD12Nz6yNlg4KM7:TR?=	NVLjbFkxW0GQR1XS
NCI-H727	M3;HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\DOWdKSzVyPUS3MlI1PTFizszN	NXvNfGRVW0GQR1XS
NY	NUjaUJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmO5TWM2OD12OT6zPVA5KM7:TR?=	MUjTRW5ITVJ?
NCI-H2291	NXPqdXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTR7LkizNFEh\|ryP	NHPie4ZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Water	Insoluble
	Ethanol	'3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	MK0683
Smiles	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Withdrawn	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA)